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The main purpose of this thesis was to investigate the influence of muscle fiber 
type composition and supplemental creatine monohydrate on repeated bouts of the 
Wingate Anaerobic Test (WAnT). More specifically, would a higher percentage of Type 
H muscle fibers demonstrate a greater significant improvement in repeated bouts of cycle 
ergometry after creatine supplementation. Nineteen males (mean ± SD age, body mass, 
and height = 21.7 ± 1.9 yr., 84.1 ± 14.1 kg and 161.5 ± 7.8 cm, respectively) participated 
in the 13 day experiment. Initially, sixty-five participants performed a single 30-s WAnT 
against a resistance of .10 kg/kg body weight. All scores were then rank ordered fi'om 
highest to lowest, according to relative peak anaerobic power (PAPr) scores. Ten 
participants fi'om both ends of this distribution were approached and requested to 
volunteer for the remainder of the study. This allowed the following four groups to be 
constructed: 1) high WAnT with creatine (n = 5), 2) high WAnT with placebo (n = 5), 3)
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low WAnT with creatine (/i = 5), and 4) low WAnT with placebo (n = 4). On days 4 and 
12 of the study, percutaneous muscle biopsies were obtained from the vastus lateralis and 
stained histochemically to determine fiber type distribution (Type n, Ua, and Ilb). This 
data demonstrated a positive, but weak relationship between peak anaerobic scores 
(relative) obtained during the single 30-s WAnT and percent type II muscle fibers 
(r = 0.52, p<0.05). Furthermore, a Spearman rank-order correlation revealed a positive 
monotonie relationship (R = 0.611, p<0.01) between the variables. Finally, a 2 x 2 
factorial ANOVA (F (1,15) = 12.8, p<0.01), revealed that the 10 participants within the 
high PAPr group had higher values for %FT, regardless of treatment. This data revealed 
that the grouping of participants according to PAPr during the single 30-s WAnT was 
reflective of their fiber type distribution in regards to percent type II muscle fibers. Five 
repeated bouts of the WAnT were performed on days 5 and 12 of the study, with each 
bout lasting 15-s, against a resistance o f0.075 kg/kg body weight and with 45-s of active 
rest between each bout. Supplementation occurred on days 7 through 11, with groups # 1 
and #3 receiving the treatment (4 x 5g of creatine + 2g of dextrose powder) and groups 
# 2 and # 4 receiving the placebo (4 x 7g of dextrose powder). Peak anaerobic power 
(absolute and relative), mean anaerobic power (absolute and relative) and percent power 
decrease were recorded during each of the five bouts. The design was a 2 (time: pre or 
post) by 2 (treatment: creatine or placebo) by 2 (WAnT: high or low) by 5 (bouts; 1 
through 5) split-plot factorial analysis. Change scores were calculated for all five 
dependent measures and consequently the data was analyzed with a 2 (treatment; creatine 
or placebo) by 2 (WAnT: high or low) by 5 (bouts: 1 through 5) split-plot factorial 
ANOVA, which revealed no significant main or interaction effects. Furthermore, there
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was a significant increase in body weight, from pre to post-supplementation, regardless of 
treatment. The results therefore, suggest no relationship between participants' fiber type 
distribution (through the stated relationship to PAPr), creatine supplementation, and 
repeated bouts of the WAnT. However, due to the small number of participants per cell 
or group within this study, the results should be viewed with caution.
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CHAPTER 1 
INTRODUCTION
Statement o f the problem
The main purpose of this thesis was to investigate the influence creatine 
monohydrate supplementation and muscle fiber type composition on five repeated bouts of 
the Vringate Anaerobic test (WAnT). More specifically, did a higher percentage of Type 
n  muscle fibers demonstrate a significant improvement during any or all bouts of the 
WAnT?
Significance of the study
In this day and age, athletic competition can place enormous pressure on those 
involved to be successful, and consequently, ergogenic aids are used by many amateurs 
and professionals. One particular ergogenic aid, creatine (Cr), has become a widely used 
nutritional supplement by both high caliber and recreational athletes. In fact, Bolotte 
(1998) stated that approximately 80% - 90% of professional football players and track 
and field athletes have used creatine. Furthermore, creatine is not currently banned by any 
major sport governing bodies, including the International Olympic committee, since it is 
not considered an illegal chemical substance (McArdle, Katch, & Katch, 1999). 
Consequently, creatine has become one of the most popular ergogenic aids in the sport 
supplement market over the past decade.
Normal total creatine resting values (creatine and phosphocreatine) are on average 
124 mmol'kg'^ dry muscle (dm), with 95-98% located within skeletal muscle and the
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
remaining 5% found primarily in heart, brain, liver, kidney and testicle tissue (Balsom, 
Soderlund, & Ekblom, 1994; Ekblom, 1996; Harris, Soderlund, and Hultman, 1992).
The esdcular importance of phosphocreatine (PCr) can be realized when one 
reviews its role in bioenergetics. Adenosine triphosphate (ATP) is the human energy 
currency and facilitates digestion, circulation, tissue synthesis, nerve conduction, glandular 
secretion, and muscular contraction (McArdle et al., 1999). An increase in creatine stores 
should allow for prolonged use of phosphocreatine in resynthesizing ATP anaerobically, 
which in turn decrease reliance on anaerobic glycolysis (McArdle et al ). This is beneficial 
to repeated bouts of intermittent, high intensity performance, as anaerobic glycolysis will 
produce lactic acid levels that result in a decrease in pH and ultimately affect performance 
in a negative maimer.
Muscle fiber type distribution most likely regulates initial creatine levels and 
uptake for any given individual. Type II muscle fibers have a higher resting concentration 
of PCr than Type I muscle fibers and greater phosphocreatine utilization, with a slower 
rate o f resynthesis of phosphocreatine during repetitive bouts of intermittent, high intensity 
exercise (Tesch, Thorsson, and Fujitsuka, 1989; Soderlund, Greenhaff^ and Hultman, 
1992). Also, Greenhaff, Bodin, Soderlund, and Hultman (1994) reported that Type II 
muscle fibers have approximately 45%-55% higher values of creatine than do Type I 
muscle fibers. Furthermore, Type lib, fast twitch muscle fibers, have been shown to store 
4-6 times more phosphocreatine than ATP (Casey, Constantin-Teodosiu, Howell,
Hultman, and Greenhaff, 1996). These findings illustrate that muscle fiber type 
distribution plays an integral role in creatine uptake and utilization during exercise and 
therefore those individuals with a higher percentage of Type II muscle fibers would be
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
expected to outperform subjects with lower concentrations of Type II muscle fibers during 
repeated bouts of intermittent, high intensity exercise.
To date, previous studies investigating the uptake of creatine and repeated bouts 
of intermittent high intensity exercise, such as the WAnT, have not grouped participants 
according to fiber type, or in groups of high or low percentage of Type II muscle fibers. 
Positive correlations ranging fi'om 0.54 to 0.81 have been reported between relative peak 
anaerobic power (PAPr) scores achieved during a single 30-s WAnT and muscle fiber type 
distributions (Bar-Or et al, 1980; Froese and Houston 1987; Inbar, Kaiser, and Tesch, 
1981; Kaczowski, Montgomery, Taylor and Klissouras, 1982). _Although the groups 
within this study were formed on the basis o f PAPr, the aforementioned correlations 
should allow some conclusions to be drawn in regards to the role that fiber type 
distribution had in creatine supplementation and repeated bouts of the WAnT.
Delimitations
1) The original 65 male participants for this study were students at Lakehead
University, ranging in age firom 19- 27 years old. The final 19 participants were selected 
on the basis of PAPr scores obtained during the single 30-s WAnT.
Limitations
1) It was assumed that at all times during the single and repeated bouts of the WAnT, 
all participants gave maximal effort.
2) The accuracy of participants in recording their nutritional intake during the study 
was a limiting factor.
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3) AU instruments used in the collection and analysis of data were in themselves 
limiting factors.
4) It had to be assumed that the manufacturer accurately described the purity and 
quality of the creatine monohydrate.
Definitions
Creatine is an organic compound obtained predominantly from ingestion of meat 
or fish, which contains «5 g of Cr kg*̂  (Volek & Kraemer, 1996). Furthermore, creatine 
is synthesized primarily within the liver, pancreas, and kidney by means of the precursor 
amino acids glycine, the guanidino group of arginine, and methyl group from S- 
adenosylmethionine (Murray, Granner, Mayes, & RodweU, 1996).
Creatinine is formed through the degradation of creatine and phosphocreatine and 
is formed at a slow and constant rate through a nonenzymatic, irreversible reaction 
(Volek and Kraemer, 1996).
Mean Anaerobic Power (MAP) is the total number of revolutions of the flywheel 
during the performance, divided by 30 (30 seconds of total cycling). It is also defined as 
the total power output divided by 30 seconds, which can be expressed in relative (MAPr) 
or absolute (MAPa) terms (Inbar, Bar-Or, and Skinner, 1996). Mean anaerobic power is 
calculated as follows:
M P  (Watts) = Total Work (Watts) / 30 (seconds)
Peak Anaerobic Power (PAP) is the maximum number of revolutions of the 
flywheel in a 5-s period. Is also defined as the maximum power output attained during S-s
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
of qrcle ergometry, which can be expressed in relative (PAPr) or absolute (PAPa) terms. 
(Inbar et al., 1996). Peak anaerobic power is calculated as follows:
PAP (Watts) = Force x Distance /  Time [N x (Max Revs x 6 metres)] / 5sec 
Phosphocreatine is the phosphorylated derivative of creatine found within muscle 
and is a high-energy compound that can reversibly donate a phosphate group to ADP to 
form ATP (McArdle et al., 1999).
Rate of Fatigue (Fatigue Index) is the numerical difference between the highest 
number of flywheel revolutions and the lowest number of flywheel revolutions, expressed 
as a percent of peak power (PP) (Inbar et al., 1996). Rate of fatigue is calculated as 
follows:
Rate of Fatigue = [(Peak Power (W) - Lowest Anaerobic Power (W)) / Peak 
Power] X 100




A historic overview o f creatine (Cr) and its applications to athletic performance is 
a logical first step in discussing creatine supplementation. Creatine was initially 
discovered by the French scientist, Chevreul, in 1832 (Greenhaff 1994). However, due to 
technological limitations in detecting creatine, no significant advances were made until 
1847, when Lieberg confirmed that creatine was a regular component of muscle extracted 
fi'om mammals (Greenhaff 1994). Furthermore, Lieberg reported that muscle samples of 
wild foxes killed in chase contained ten times more creatine than captive animals and 
concluded that muscle activity resulted in an increase in creatine (Demant and Rhodes, 
1999). In retrospect, this is understandable, as wild foxes would be prone to fi'equent 
bursts of sprinting during daily hunting sessions. Shortly thereafter, Heintz and 
Pettenkofer discovered a urinary product that Lieberg later confirmed to be creatinine, a 
metabolic end-product of creatine degradation (Balsom et al., 1994). From the 
observation that creatinine excretion was related to muscle mass, it was postulated that 
creatinine found in urine was directly linked to creatine levels within muscle (Balsom et 
al., 1994)
During early creatine feeding studies, Chanutin (1926) noted that not all ingested 
creatine could be accounted for in urine samples and speculation arose that some 
unspecified quantity of creatine was retained by the body (as cited in Greenhaff, 1995). 
The specific site of exogenous creatine uptake within the body was somewhat clarified in
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
1912 and 1914 by Folin and Denis, who reported that muscle levels increased by nearly 
70% in cats that were fed creatine (Balsom et al., 1994).
The first attempt at quantifying the amount of creatine contained within man came 
about in 1923 by Hahn and Meyer, who estimated that total creatine content of a 70 kg 
male to be approximately 140g (Greenhaff 1995). The next major development in 
creatine research came in 1927 when Fiske and Subbarow first reported phosphocreatine 
(PCr) as a “labile phosphorous” in resting cat muscle, with levels dropping during 
muscular electrical stimulation and reappearing during the ensuing rest period (Balsom et 
al., 1994). From this early research, it became evident that creatine and phosphocreatine 
were vital to energy metabolism and that an increase in resting creatine muscle levels 
could be advantageous to certain athletic events (Volek and Kraemer, 1996).
To aid in understanding the role of creatine in muscle metabolism, researchers 
began to rely on the muscle biopsy technique that Bergstrom implemented in 1962 while 
studying muscle electrolytes in man (Demant and Rhodes, 1999). Hultman, Bergstrom, 
and Anderson (1967) reintroduced the muscle biopsy technique to study the breakdown 
and resynthesis of ATP and PCr with exercise in humans. A more recent development in 
muscle metabolism research was the implementation of magnetic resonance spectroscopy 
(MNR) (Demant and Rhodes, 1999).
What is Creatine?
Creatine is a nitrogenous organic compound (methylguanidine-acidic acid), that 
can be thought of as a specialized product synthesized primarily in the liver, kidneys, and 
pancreas fi'om the precursor amino acids arginine, glycine, and methionine (Murray,
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Granner, Mayes, and Rodwell, 1996). In general, arginine will donate a guanidine group 
to glycine and form guanidoacetate, which is then methylated in the Uver by S- 
adenosylmethionine, with the end result being the formation of creatine (Murray et al., 
1996.) The role of creatine is to ultimately combine with a phosphate group to form 
phosphocreatine, which in turn is used to rephosphorylate adenosine diphosphate (ADP) 
to ATP (McArdle et al., 1999). Research has shown that a daily requirement of creatine 
(2g) is needed, either exogenously or endogenously, since it and phosphocreatine have 
been shown to degrade in an irreversible, nonenzymatic reaction at an approximate rate of 
1.6% per day (Crim, Calloway, and Margen, 1976; Ekblom, 1996; Volek & Kraemer, 
1996). As an example, a 70 kg individual would have a total creatine pool of 120 g and 
approximately 2 g would be replaced on a daily basis (Balsom et al., 1994). Creatine can 
be ingested by consuming fish and meats, which contain approximately 5 g Cr kg '\ or as a 
nutritional supplement (creatine monohydrate) in a powder, tablet, capsule, or stabilized 
liquid form (McArdle et al ).
Role of Creatine in Exercise
Creatine is essential in the bioenergetics of ATP production via phosphorylation, 
the process of storing energy as ATP fî om other chemical sources (V^more & Costill, 
1994). Unlike ATP, the energy derived fi-om phosphocreatine is not used directly to 
accomplish work, but to rephosphorylate adenosine diphosphate (ADP) to ATP (Wilmore 
& Costill, 1994). The above process is aided by the enzyme creatine kinase (CK), which 
removes a phosphate fi’om PCr and couples it to ADP, creating ATP ()^lmore & Costill, 
1994). This energy system is known as ïa&ATP-PCr system, which is presented below in
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
figure 1 and the key reaction responsible for the rephosphoiylation of ATP is known as 
the creatine kinase reaction.
Figure 1. Creatine kinase reaction
Phosphocreatine + ADP ^ ——^  ATP + Creatine
However, it is generally agreed upon by most researchers in exercise physiology, 
that creatine is an essential energy substrate only during very specific forms of exercise, 
such as short bursts of muscular activity (McArdle et al., 1999).
A second crucial role of creatine during high intensity exercise is to act as a spatial 
energy buffer through a process known as the “phosphocreatine energy shuttle” (McArdle 
et al., 1999). This process involves the difiusion of creatine and phosphocreatine between 
sites of utilization and production of phosphocreatine. This system is comprised of a 
peripheral terminus for phosphocreatine utilization (myosin head for muscle action), an 
energy production terminus located within the mitochondria, and an intervening space 
between the sites (Volek & Kraemer, 1996). The aforementioned process is best 
understood in the following diagram of figure 2.
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Figure 2. Phosphocreatine Energy Shuttle
Energv-Production Terminus \  Intervening Space f  Peripheral-IJtilization Terminus 
mitochondria J  l  myosin head
,pCr + ADP + Ht*SK.Cr + A TB / Cr PCr + ADP + lT ^ ^ C r  + A]
PCr----------►
At the peripheral terminus, phosphocreatine donates its phosphate in order to 
rephosphorylate ADP, so that ATP demand is fulfilled and exercise can continue. In the 
process, creatine is liberated and travels back to the energy-production terminus via the 
intervening space (in the opposite direction of phosphocreatine) were it can than be 
utilized to produce more phosphocreatine, which will return to the peripheral terminus to 
rephosphorylate ADP and compete the shuttle (Volek & ECraemer, 1996).
A third reported beneficial function of creatine is its ability to buffer excess protons 
(HO produced during ATP production. Accumulation of lactate results in an increase in 
H , which will decrease the cell pH and performance of the muscle will be negatively 
affected. Fortunately, when the creatine kinase reaction is in the process of producing 
ATP, H  are utilized and a normal pH is maintained (Volek & Kraemer, 1996).
A fourth noted benefit of creatine is as a mediator of glycolysis during exercise. At 
the commencement o f intense exercise, glycolytic demand can increase up to a hundred 
fold and phosphocreatine levels drop dramatically so that ATP may be rephosphorylated at 
the active muscle sites (Volek & Kraemer, 1996). Some in vitro research implies that low 
levels of phosphocreatine may play a role in stimulating glycolysis. It has been suggested
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that phosphofiuctokinase (PFK) is conceivably inhibited at certain physiological 
concentrations of phosphocreatine, but that during strenuous exercise when 
phosphocreatine levels drop, PFK is activated and glycolysis is initiated with the end result 
of more ATP production for active muscles (Volek & Kraemer, 1996).
Muscle Fiber Types and Creatine
It is generally agreed upon that Type H muscle fibers have higher basal levels of 
phosphocreatine than in Type I muscle fibers (Tesch, Thorsson, and Fujitsuka, 1989). 
Furthermore, human studies have shown that creatine kinase activity is higher in type n  
than in type I muscle fibers (Jansson and Sylven, 1985; Thorstensson, Sjodin, Tesch, and 
Karlsson, 1977). This higher enzyme concentration in Type II muscle fibers most likely 
indicates that these muscle fibers do indeed have higher basal levels of phosphocreatine 
than do Type I muscle fibers. This could imply that individuals with higher concentrations 
of Type n  fibers would retain more supplemental creatine and perform more favourably in 
intermittent, repeated bouts of maximal exercise than individuals with lower 
concentrations of Type II muscle fibers.
It is also important to note the relationship between power measurements obtained 
during exercise performance and fiber type distribution. Since its development in the 
1970s, the Wingate Anaerobic Test (WAnT) has become the most widely used test in 
assessing muscular power, endurance and fatigability in humans (Inbar, Bar-Or, and 
Skinner, 1996). Furthermore, the WAnT is a simple, inexpensive and noninvasive 
technique, which is in direct contrast to the procedure of obtaining a muscle biopsy. In 
addition, power indices obtained fi*om the WAnT have been positively correlated to leg
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muscle fiber type composition (Inbar et al., 1981). For example, correlations of r = 0.54 
and r = 0.57 were reported between PAP (WAnT) and percent Type II muscle fiber . 
distribution (Bar-Or et al., 1980; Inbar et al., 1981). Furthermore, PAP and total work 
(TW) have also been correlated with fiber type distribution (percent Type H).
Correlations of r = 0.59 (PAP), r = 0.81 (TW), and r  = 0.81 (PAP), r = 0.62 (TW) were 
reported by Kaczkowski et al. (1982), and Froese and Houston (1987) respectively. 
Therefore, grouping participants according to PAPr scores obtained during a single 30-s 
WAnT should also reflect fiber type distribution according to these previously reported 
relationships.
Creatine SupDlementatlon
Creatine supplementation, with the hope of augmenting athletic performance, is 
prevalent at all levels o f organized sport. As previously stated, up to 80-90% of 
professional football players and track and field athletes have used creatine monohydrate 
in supplemental form at one point (Bolotte, 1998). Creatine supplementation made media 
headlines during the 1992 Summer Olympic Games, due to claims of the ergogenic effect 
of creatine supplementation by British sprinters and hurdles (McArdle et al., 1999). This 
is not surprising since creatine is essential for intermittent, repeated bouts of maximal 
exercise and has been shown to be retained in the body to some extent. Normal resting 
plasma concentrations of creatine are in the range of 50-100 pmol/L and ingesting 5 g of 
creatine in solution will raise plasma concentration levels to 600-800 pmol/L within 1 hour 
(Green, Hultman, Macdonald, Sewell, and GreenhaflF, 1996; Harris et al., 1992). Creatine 
uptake into muscle cells occurs against a concentration gradient, by means of a family of
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Nà** dependent neurotransmitter transporters (Guimbal and Kilimann, 1993).
Furthermore, increases in muscle creatine levels can be augmented by ingesting c rea te  in 
combination with carbohydrates (Green et al., 1996). It is generally accepted that 20 
g/day of creatine (4 x S g doses/day) for 5 days will on average increase muscle creatine 
levels by 20%, of which 20% is in the phosphorylated form (Greenhafi^ Constantin- 
Teodosiu, Casey, & Hultman, 1994; Harris, Soderlund, & Hultman, 1992). Similar results 
have been reported when 3 g/day for 28 days was utilized (Hultman, Soderland, Timmons, 
Cederblad, and Greenhaff, 1996). The greatest gains in total Cr have been in those 
individuals with the lowest initial values (118 mmol kg'^dm) and there is speculation that 
vegetarians would have the largest gains in creatine uptake due to low initial stores 
(Balsom, Ekblom, Soderlund, Sjodin, and Hultman, 1993; Harris et al., 1992; Delanghe et 
al., 1989). The uptake of creatine appears most significant during the initial days of 
supplementation, as illustrated by Harris et al. (1992) when they reported 70% retention 
on day 1, but nearly 0% on day 7. This has led to the conclusion that there is an upper 
limit, or saturation point of creatine uptake, of approximately 160 mmol kg'  ̂(Harris et al., 
1992). However, the determining factors that regulate whether an individual has high or 
low concentrations of creatine in their muscle remains unknown and is in need of further 
research (Greenhaff, 1994).
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Side Effects o f Creatine SuDPlemcntation
To date, the only consistently reported side effect with short-term, oral creatine 
supplementation has been a statistically significant increase in body mass fi-om 0.5 kg to 
2.4 kg (McArdle et al., 1999). The largest increases have been in those who possess low 
initial values, most notable vegetarians (Harris et al., 1992). Reduced urinary volume 
during creatine supplementation suggests that an increase in body mass can be attributed 
to excess water retention (Hultman et al., 1996). Another possible cause for increases in 
body mass, is a significant augmentation in lean body mass after creatine supplementation. 
Six weeks of strength training and creatine supplementation (20g/day for 7 days, 2g/day 
thereafter) resulted in significant increases in fat fi-ee mass for 23 male participants 
(Becque, Lochmann, and Melrose, 1997). To date, it is accepted that water retention and 
increases in lean body mass are the most likely causes for the significant increases in body 
mass with creatine supplementation (Williams and Branch, 1998).
The purity of supplemental creatine has been called into question as a possible 
health risk and certain guidelines to be fiallowed when purchasing creatine are available 
(McArdle et al., 1999). These same researchers claim that the increase in body mass could 
be fi-om the anabolic effect of Cr on muscle synthesis, water retention within muscle cells, 
and/or other unknown factors. Furthermore, anecdotal reports fi-om numerous athletic 
trainers suggest a possible link between creatine supplementation and muscle cramps, 
muscle spasms, and pulled muscles (Clarkson, 1998).
To a large extent, much of the controversy surrounding creatine supplementation 
came about with an anecdotal report that surfaced in December of 1997, in which it was
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suggested that creatine supplementation was partially responsible for the deaths of three 
American collegiate wrestlers (Clarkson, 1998). As a result of creatine supplementation, 
these wrestlers were likely experiencing difficulty "making weight" due to excess water 
retention within muscle cells. This could have caused the wrestlers to use even more 
drastic means of losing weight than normally practiced and the excessive state of 
dehydration that can be induced most likely resulted in fatal thermal stresses (Clarkson, 
1998).
Many researchers have noted a lack o f information regarding the long-term side 
effects o f creatine monohydrate supplementation. Juhn and T am opolslgr (1998) provide 
an excellent literature review in which possible negative side effects of long-term creatine 
supplementation were listed. These included: cardiovascular, gastrointestinal/liver, 
musculoskeletal, neurologic, oncologic, pediatric/adolescent, renal (kidney), reproductive 
organs, weight gain, and dehydration. One o f these aforementioned organ systems, the 
kidneys, has been cited in numerous articles related to creatine supplementation. It is 
theorized that the one carboxyl and two amino groups of creatine, as well as the high 
nitrogen content (32%) could place excessive and perhaps dangerous amounts of stress on 
the kidneys (Poortmans et al., 1997). More controversy surfaced when Pritchard and 
Kalra (1998) reported that a patient under their care presented "substantial" renal 
dysfunction while taking oral creatine supplementation (15g/day for 7 days, 2g/day for 7 
weeks thereafter). The individuals' renal functions returned to within the normal range 
only after creatine supplementation ceased (Pritchard and Kalra, 1998). However, it must 
be noted that tliis report involved only a single participant, who was suffering from focal
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segmental glomerulosclerosis for 8 years before creatine supplementation. A more recent 
and unsettling development pertains to a report by the French Food Safety Agency, m 
which they claim that long-term oral creatine supplementation constitutes "a potential 
carcinogenic risk" ("Creatine linked," 2001).
Creatine SuDPlementation Research
A table format was utilized on the following pages to present to the reader a 
simplistic means of reviewing literature related to creatine supplementation and athletic 
performance. Forty-three (43) articles were reviewed in hopes of determining why 
specific findings were reported, with the following categories being used: creatine dosage, 
performance protocol, measurements for analysis, participant pool, results, and reasons for 
findings. Each article was categorized as being either "statistically significant" or " 
statistically nonsignificant" in terms of the results. Although not all-vital information was 
contained within these tables, it should provide a quick reference source for any individual 
interested in creatine supplementation research to date.































Barnett et al., 4 X 70 mg/kg"' •7  X 10s cycle •peak power •  10 active males •C r had no •C r dosage did not elevate
1996 body mass Cr/day ergometer •m ean power influence on resting muscle Cr levels?
mixed with 5g •30s recovery for •end-power output any parameter •only speculation as no
glucose for 4 days sprints 1-5, 6-7 •%  power decline tissue, blood or urine was
•5 min. recovery for collected
sprints 5-6
Febbraio et •20g Cr/day for 5 •4x60s cycle ergometry •adenelytes •6  active & untrained •C r had no •duration o f  exercise is not
al., 1995 days with 60s rest at 115- •ammonia males influence on heavily influenced by the
•crossover design 125% VO2 max •PCr any parameter ATP/PCr pathway
with 4 week •1 exhaustive sprint •Cr
washout period •glycogen 
•blood lactate
Cook et al., 4 x 5 g C r +  Ig •  1 X 15s cycle •peak power (pp) •  12 healthy untrained •no significant •free Cr increased by PCr
1995 glucose for 5 days ergometry •tim e to pp men differences did not?
•20  min. rest •total work between or •only speculation as no




Odiand et al., 20g Cr/day for 3 •3 randomly ordered •peak power •9  healthy males •C r had no •  Cr dosage did not elevate
1997 days Wingates «14 days apart •  10s power effect for any resting muscle Cr levels?
•creatine •30s power measured •only speculation as no
•placebo •%  fatigue parameter tissue, blood or urine was
•control •post-exercise blood 
lactate levels
collected
Balsom, 4 x5gC r+ lg •exhaustive treadmill •performance time •18 habitually active •C r had no •C r (ATP/CP sys) is not a
Harridge, et glucose for 6 days run •VO2 & heart rate to well-trained males effect for any major energy pathway for




• Î  6 km time



































RESULTS REASONS FOR 
FINDINGS
Thompson et 2g Cr/day for 6 •plantar flexion •PCr/ATP 10 highly trained Cr had no •exercise protocol was not
a l ,  1996 weeks •  10-]5min in duration •Ph
•PCr/ADP
•Qmax 
•  P c r t ]/2
•Reoxygenation i\a
female swimmers effect for any
measured
parameter
intermittent, high intensity 
in nature?
•exogenous Cr suppressed 
endogenous Cr 
production?
Mujika et al., 4x5g Cr/day for 5 •swimming test •blood lactate •20  highly trained •significant t •participants were elite and





•  9 females
•  11 males
in bw





•  significant i  
in post 50m 
ammonia 
levels (PI)
•C r had no 
other effect
perhaps already at upper 
limits in terms o f  resting 
muscle Cr levels?
• t  in bw resulted in slower 
performance time?
Earnest, Rash •20g Cr/day for 4 •2x treadmill runs until •blood lactate 11 male subjects Cr had no •participants were elite and
et al., 1995 days
•then lOg Cr/day 
for 6 days
exhaustion
•runs lasted around 90s 
and 8 min recovery 
period
•performance time effect for any
measured
parameter
perhaps already at upper 
limits in terms o f resting 
muscle Cr levels?
•T in bw resulted in slower 
performance time?
•  rest period sufficient for 






































Redondo et •25g mix o f  Cr •3x60m runs •velocity (m/s) •32 subjects Cr had no •m ore trials needed to
al., 1996 and glucose for 7 •2min rest periods •highly trained mixed effect for any induce a state o f  fatigue?
days athletes measured •  rest period sufficient for
•83%  o f  mix Cr •14 females 
•8  males
parameter PCr resynthesis regardless 
o f  supplementation?
•C r dosage did not Î  
resting muscle Cr levels
Odiand et al.. •20g Cr/day for 3 • I x  wingate cycle test •peak power 9 male subjects Cr had no •exercise protocol was not
1994 weeks •mean 10s power effect for any intermittent, high intensity
•crossover design •mean 30s power measured in nature?
•14 washout •%  fatigue parameter •C r (ATP/CP sys) is not a
phase •  blood lactate major energy pathway for 
exercises in excess o f  30s 
•m ore trails needed to fully 
induce a state o f  fatigue? 
•C r dosage did not elevate 
resting muscle Cr levels?
Rossiter et al.. 5x.25g Cr/kg 1000m simulated •creatine uptake •38 competitive •C r had no •exercise protocol was not
1996 body mass/day for rowing performance (% o f intake) rowers effect for intermittent, high intensity
5 days •creatine uptake 
(gkgBM * )
•28 males performance in nature?
•10 females time •C r (ATP/CP sys) is not a
•performance time (r =0.426) major energy pathway for 
exercises in excess o f  30s
Burke et al.. 4x5g Cr+2g •sw im m ing test •  swimming test •32 elite swimmers Cr had no •C r dosage did not elevate
1996 glucose for 5 days •25m,50m,&100m •performance time •14 females effect for any resting muscle Cr levels?
•lOmin rest periods •blood lactate •18 males measured •participants were elite and
•b ike  test •b ike test parameter perhaps already at upper
•2x1 Os cycle ergometry •peak power limits in terms o f resting
•lOmin rest •work done muscle Cr levels?






































RESULTS REASONS FOR 
FINDINGS
Terrillion et 20g Cr/day for 5 •2x700m runs •performance time 12 well-trained & Cr had no •89%  o f t  in Cr pool was








•  rest period sufficient for 
CP resynthesis regardless 
o f  supplementation?
Rawson et al.. •20g Cr + 28g •3 maximal isometric •Body mass •20  healthy male •C r had no Uptake o f Cr into muscle
1999 dextrose powder contractions o f  elbow •Body composition participants significant cell impeded due to age o f
for 10 days 
•Continued by 4g 
Cr + 6.8g o f 
dextrose for 
following 20 days 
•  1 serving o f 
Gatorade 
ingested 30-min 
after ingestion o f  
supplementation
flexors with 60-s rest 
•5x30 knee extensions 
@ 180°
•  1x30 max contractions 
•underwater weight to 
determine body 
composition
•Arm isometric strength 
•Leg fatigue 
•Peak fatigue




Francaux et •21 g Cr/day for 5 •6-week training •body water content •25 healthy males •no significant •exercise protocol was not
al., 1999 days then 3g 
Cr/day for 58 
days





6x6 squats at 30% o f 
max
•workload T to last 
week which had 8x6 
squats at 42.5% o f max 
•3 -weeks of 
supplementation, but no 
training
•isokinetic force 
•  single squat used for 
data analysis
improvements 
in any o f  the 
parameters 
after 6 weeks 





































Table 5. Significant effect o f creatine supplementation on exercise performance.







RESULTS REASONS FOR 
FINDINGS
Earnest et al., 4 X 5g Cr + Ig 3x3 wingate test with •anaerobic capacity 8 weight trained t  in anaerobic •  Cr dosage did elevate
1994
glucose for 14 
days
Smin rest periods •peak anaerobic power 
•plasm a ammonia
males capacity with 
Cr
resting muscle Cr levels? 
•exercise protocol was 
appropriate?
Earnest, wineate: wingate: wingate: •8  males wingate: •  Cr dosage did elevate
Snell, et.. 20g Cr/day for 14 3 wingate test with • k j  during the 3 test •at least 10 years t  in work done resting muscle Cr levels
1995 days 5min rest periods muscular strength: experience in weight (kJ) for all 3 •exercise protocol was
muscular
strength:
20g Cr/day for 28 
days
muscular strength:
•1 RM bench press 
•repetitions o f  70% o f 1 
RM bench press
1 RM bench press 
•absolute (kg) 
•relative (kg k g ’ ) 
Lifting reps-70% IRM  
•num ber o f  reps 
•absolute (kg) 




1 RM bench 
press
• t  absolute 
Lifting reps- 
70% IRM  







Harris et al.. 6x5g Cr + 5g •4x300m runs- 3 min •performance times •10 trained middle significant i  in •  Cr dosage did elevate
1993 glucose/day for 5 
days
rest
•4x1000m runs - 4min 
rest




resting muscle Cr levels? 


































Table 6. Significant effect of creatine supplementation on exercise performance.















4x5g Cr + Ig 
glucose/day for 7 
days 
test 2;
additional 2 days 
o fC r
supplementation
Kreider et al., 
1998
test 1;
•5x15s cycle ergometry 
Imin rest period 
test 2;
•5x60s cycle ergometry 
5min rest period
15.75g Cr/day for 
28 days
•  4x5g Cr/day for 
5 days




•w ork (kJ) 
•total work (kJ)
•%  decrement in work
•12x6s cycle ergometry 
















•9  untrained 
participants
28 NCAA division 
LA football players
•  16 male physical 
education students
•significant t •  Cr dosage did elevate
in work resting muscle Cr levels?
performed •exercise protocol was
during all 5 appropriate?












greater gains •C r dosage did elevate
for Cr group in resting muscle Cr levels
•fat/bone-free after 28 days?





•C r loading i •exercise protocol was
relaxation time appropriate?
needed •C r dosage did elevate








































RESULTS REASONS FOR 
FINDINGS
Greenhaff et 4x5g C r+ lg •5x30s maximal •muscle torque •  12 physically active. • t  muscle •  Cr dosage did elevate
al., 1993 glucose/day for 5 voluntary isokinetic •ammonia but non-highly torque for resting muscle Cr levels
days contractions 
•1-min rest periods





•21-30 o f bout 
l ,a ll
contractions 
for bouts 2, 3 
& 4  & 11-20 
o f bout 5




Jacobs et al.. 20g Cr/day for 5 cycle ergometry until •maximal accumulated 26 participants • Î  in time to •  Cr dosage did elevate
1997 days exhaustion 
•125%  VO; max
0; deficit
•tim e to exhaustion




•  maximal 
accumulated 0; 
deficit T (Cr 
group)
resting muscle Cr levels? 
•  findings are contrary to 
most involving the lactic 
acid energy system & 
exercise lasting 30-150- 
seconds






















resting muscle Cr levels 





































Table 8. Significant effect of creatine supplementation on exercise performance.




Prévost et al., •5 X 3.75g Cr/day •4  cycling protocols to •total work times •physically active & •C r Î  time to •  Cr dosage did elevate
1997 for 5 days (18.75 exhaustion •plasma lactic acid healthy subjects exhaustion resting muscle Cr levels?
g) A) continuous •  10 males & 8 (total work •exercise protocol was
•  1 X 2.25g C r/day B) repeated 30s, with females output) appropriate?
for next 6 days 60s rest regardless or •appropriate participant
(13.5g) C) repeated 20s, with work protocol pool?
40s rest •plasma lactate
D) repeated 10s, with accumulation
20s rest i  following Cr
Dawson et al., 4 x 5 g C r+  Ig study 1: study 1: study 1: study 1: •  Cr dosage did elevate
1995 glucose + 0.2g IxlOs cycle ergometry •work done (kJ) at 2s, 18 healthy, active Cr had no resting muscle Cr levels?
calcium carbonate study 2: 4s, 6s, 8s, & lOs males effect for any •exercise protocol was
for 5 days •6x6s cycle ergometry •total (J kg ‘ ) study 2: measured appropriate only in study
•24s rest periods •peak power (W) 22 healthy, active parameter two (repeated bouts)
•peak power (W kg"’ ) males study 2; •appropriate participant
•blood lactate and pH •total work t pool
study 2: (Jk g  ■' and kJ)
•W ork done (kJ) for rep •peak pow ert
1,6 and total work •work done in
•  total (] kg ' ) repetition 1 T
•peak power (W) •Peak Power Î
•peak power (W kg"’ ) (W)
•%  decrement






























Table 9. Significant effect o f creatine supplementation on exercise performance




Balsom, 5x6g C r+ lg •10x6s cycle ergometry •blood lactate •16  highly motivated •blood lactate •  Cr dosage did elevate
Ekblom, et glucose/day for 6 •30s rest periods •hypoxanthine male physical i  for Cr group resting muscle Cr levels?
al., 1993 days •resistance was •oxygen uptake education students for both •exercise protocol was
I30rev/min or •exercise performance I30rev/min appropriate?
140rev/min and •appropriate participant
•24 hrs separated the I40rev/min pool?
above protocols •hypoxanthine







rev/min for Cr 
group)




Birch et al., 4x5g Cr/day for 5 •3x3 Os cycle ergometry •peak power - PP (W) 14 healthy males •significant Î •  Cr dosage did elevate
1994 days •4min rest periods •m ean power - MP (W) in PP bout 1 resting muscle Cr levels?
•80rpm •work done (J kg ' ) 
•ammonia 
•blood lactate
•significant Î  
in MP bouts 1 
and 2
•significant t  
in work done 
during bouts 1 
and 2




























Table 10. Significant effect of creatine supplementation on exercise performance.







RESULTS REASONS FOR 
FINDINGS
Balsom et al., 
1995
20g Cr/day for 6 
days
Part 1;
•5x6s cycle ergometry 
•30s rest periods 
Part 2;
•40s after bout 5 o f part 
1
•  1x1 Os cycle ergometry 
Part 3:
•series o f  counter 
movement jumps and 
jump squats 
•before & after 
administration period
•blood lactate






7 highly motivated 
male participants
• T  in body 
weight
•C r group better 
able to  maintain 
power output 
during Part 2 
• Î  in TCr levels 
following 
supplementation 
•PCr t  and 
muscle lactate i  





•  Cr dosage did elevate 
resting muscle Cr levels? 







Volek et al., 
1999
25g Cr/day for 7 
days
•  4 sets X 10 reps o f 
jump squat @ 30% o f 1 
RM (2 min. rest 
periods)
•  1 set bench press to 
fatigue @ 80% o f 1 RM 
•10 min. rest period 




•M uscle fiber type 
•Training quality
•  19 healthy males 
familiar with 
resistance training
•C ra  
significant 
effect on all 
parameters.
•  Cr dosage did elevate 
resting muscle Cr levels? 



































Lawrence et 4x60mg/kg body 2500 rowing ergometer •performance time •trained rowers •significant 4 •  Cr dosage did elevate
al., 1997 mass o f  Cr •body mass •minimum o f  2 years in performance resting muscle Cr levels?
•VO; max competitive rowing time for Cr •  findings are contraiy to
•peak aerobic power and 2 months in group most involving the lactic
•total VO; training •no significant acid energy system &
•blood lactate & pH •10 females & 10 difference exercise lasting 30-150-
males within groups 
found
seconds
Soderlund et 20g Cr/day for 6 •5x6s cycle ergometry •Total Cr (free Cr + •  8 male participants •better able to •  Cr dosage did elevate
al., 1994 days •30s rest periods PCr) maintain target resting muscle Cr levels?
•6th bout: 10s •body mass speed at end o f •exercise protocol was
•140 rev/min •muscle lactate 
•tim e at target speed
10s bout o f  
cycle 
ergometry 
•  t  Total Cr 
stores & bm 
• i L a & t P C r  
after 5**' bout
appropriate?
•  No control?
Theodorou et •25g Cr/day for 4 •Interval swim sessions •Performance time •22 elite male and •Significant t •  Cr dosage did elevate
al., 1999 days, then A :10x50 m •M ean interval time female swimmers in performance resting muscle Cr levels?
•5g Cr/day for 2 B : 8x100 m after 1** Cr •exercise protocol was
•





after 2™* Cr 
loading phase 
in comparison 
to results after 
1* Cr loading 
phase
appropriate?
•  findings are contrary to 
most involving the lactic 
acid energy system & 









































RESULTS REASONS FOR 
FINDINGS





•maximal & 3 
submaximal bouts o f 
isometric knee 
extensions & hand grips 
(5-min rest)
•isometric strength 
•tim e to fatigue
Stone et al.. •creatine, creatine •1 rep max o f  parallel •body composition
1999 +calcium squat & bench press •maximal strength
pyruvate, calcium •2  static vertical jumps •net peak force
pyruvate, or 15 X 5-s cycle •peak power





rest between each •total work
Peyebrune et •3x3gCr+1.5g •1x50 yard swim •performance times
al., 1998 maltodextrine+1.5 •8x50 yard swim with •heart rate
g glucose/day for 
5 days
90s rest period •Blood lactate 
•Ammonia 
•Blood pH




•14 male university 
club swimmers
•C r group 






•significant t  
time to fatigue 
during all 3 
bouts o f  knee 
extensions 
•C r and Cr + 
calcium 













• i  in time for 
repetitions 1-8
•C r dosage did elevate 
resting muscle Cr levels? 
•exercise protocol was 
appropriate?
•appropriate participants? 
•  Cr only influential on 
large muscle mass?
•C r dosage did elevate 
resting muscle Cr levels? 
•exercise protocol was 
appropriate?
•appropriate participants?
•8x50 yard swim with 
90s rest period exercise 
protocol was appropriate? 
•C r dosage did elevate 




































Table 13. Significant effect of creatine supplementation on exercise performance.




Peeters et a l , Creatine, .# testing was 1 RM •strength •35 males Significant •C r dosage did elevate
1999 phosphocreatine bench press, leg press •body composition influences on resting muscle Cr
& placebo at 20g & preacher curl •blood pressure body levels?
Cr/day for 3 days. testing at pre, 3 & 6 composition & •exercise protocol was
then lOg Cr/day weeks bench press appropriate?
for 6 week period strength •appropriate
participants?
Vukovich et •20g Cr/day for 5 •5xlO-s sprint cycle •power output •48 males actively •C r had •C r dosage did elevate
a l ,  1999 days then lOg ergometry with 40-s •PAP involved in weight significant resting muscle Cr
Cr/day for 16 rest •M AP training for at least 6 influence on levels?
days •IR M  leg press, 
extension, & curl 
•30-min rest 
•5x30 max reps with 








Pearson et al.. •5g  Cr/day for 10 •1 RM bench press. •body mass •16 male college •C r had no •C r dosage did elevate
1999 weeks squat, & power clean •strength football players significant resting muscle Cr
•maximal cybex power •power influence on levels?
test body
composition 




power, & body 
mass




McKenna et •  6x5g Cr + 5 g •5x10-s maximal cycle •PAP •14 healthy. •C r ÎT C r ,C r , •Placebo effect?
al., 1999 dextrose/day ergometer sprints •power output moderately active & PC r •Small sample size?
•4  week washout •  rest intervals o f  180-s, •cumulative work output males & females •  N o effect on
period provided 50-s, 20-s, & 20-s. •fatigue index 


























Table 14. Significant effect of creatine supplementation on exercise performance




Kirksey et al., •0.3g/kg/day for 6 •2  countermovement •vertical jum p height •36 males & females •significant •C r dosage did elevate
1999 weeks vertical jump •pow er output improvements resting muscle Cr levels?
•2  static vertical jumps •peak power for: •exercise protocol was
with 1-min rest •average power •jump height appropriate?













Stout et al.. •5 .2 5 g C r+  Ig •pedaling at 70 rpm •body weight •26  healthy males •no significant •C r dosage did elevate
1999 C H O o r5 .2 5 g C r then adding appropriate •anaerobic working changes on resting muscle Cr levels?
+ 33gCH O power output at 2-3-s capacity body •exercise protocol was
•4  times/day for 6 •terminated when 65 composition appropriate
days rpm could not be •significant •appropriate
maintained influence on participants?
AWC
Kamber et al., •20g Cr/day for 5 •  10 x 6 -s  cycle •blood lactate •10  well trained sport •significant t •C r dosage did elevate
1999 days ergometry sprints with •C r & creatinine levels students in sprints ( 2 - 4 resting muscle Cr levels?
•double blind 30-s rest periods in blood & urine sec) for bouts •exercise protocol was
cross-over design •muscle volume 4 -7 and (4 - 6 
sec) for bouts 
8-10.









In reviewing the articles of “statistically nonsignificant”, it appeared that one or 
more of the aforementioned categories contained inappropriate procedures. For example, 
several studies had appropriate performance protocols, but the creatine dosage was likely 
inadequate to significantly raise resting muscle creatine and phosphocreatine levels 
(Odiand et al., 1994; Cooke, Grandjean, & Barnes, 1995; Barnett, Knds, & Jenkins,
1996). Furthermore, if the creatine dosage was satisfactory, then other design flaws were 
apparent, such as, inappropriate participant pools. That is, inappropriate participant pools 
(elite anaerobic athletes and elderly participants) were utilized in some studies (Balsom, 
Harridge, Soderlund, Sjodin, and Ekblom, 1993; Earnest, Rash, Snell, Almada, and 
Nfitchell, 1995; Mujika, Chatard, Lacoste, Barale, and Geyssant, 1996; Redondo,
Dowling, Graham, Almada, and Williams, 1996). Also elite anaerobic athletes, through 
years of high caliber training, are likely near the creatine saturation point and would gain 
little to no benefit through creatine supplementation (Harris et al., 1992). As well, elderly 
participants are thought to have a decreased ability to uptake creatine into their muscle in 
comparison to younger participants (Rawson, Wehnert, and Clarkson, 1999).
Furthermore, unsuitable performance protocols were included in some studies.
Specifically, excessive exercise duration (i.e. > 30 seconds), rest periods sufficient in time 
for phosphocreatine resynthesis regardless of creatine supplementation (i.e. > 120-180 
seconds), or insufficient number of bouts of exercise were utilized (Earnest et al.l995; 
Redondo, Dowling, Graham, Almada, and Williams, 1996; Rossiter, Carmell, and 
Jakeman, 1996; Terrilion, Kolkhorst, Dolgener, and Joslyn, 1997; Thompson et al., 1996).
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The same aforementioned categories were also scrutinized when reviewing articles 
with “statistically significant” findings. However, it would appear that the research design 
was appropriate in each of the categories. A creatine dosage regiment of approximately 
20g/day for S days was widely used and most certainly raised resting muscle creatine and 
phosphocreatine levels (Birch, Noble, and Greenhaff 1994; Greenhaff et al., 1993; 
Soderlund, Balsom, and Ekblom, 1994). Participants were most often not highly trained 
and this would allow for greater uptake of the creatine (Lemon et al., 1995; Peyrebrune, 
Nevill, Donaldson, and Cosford, 1998). Furthermore, a majority of the studies 
incorporated performance protocols that consisted of repetitive bouts of intermittent, high 
intensity exercise (Dawson et al., 1995; Earnest, Snell, Rodriguez, Almada, and Mtchell, 
1995; Scheinder, McDonough, Fadel, and Berwick, 1997).
It would appear that creatine supplementation is an effective ergogenic aid for the 
following reasons; 1) allows faster ATP turnover rate in maintenance o f power output 
during short-term muscular effort, 2) delays phosphocreatine depletion, 3) delays 
excessive reliance on anaerobic glycolysis and therefore decreases formation of lactic acid, 
and 4) facilitates recovery from repeated bouts of intermittent, high intensity exercise via 
an increased rate of ATP and PCr resynthesis and thus allows for high-level power output 
(McArdle et al., 1999). Further research is needed to fully understand those circumstances 
in which creatine supplementation would be advantageous to athletic performance. One 
such circumstance is to examine the influence of muscle fiber type composition and 
supplemental creatine monohydrate and the effect on repeated bouts of the WAnT.





This study was undertaken to determine the role that muscle fiber type and creatine 
supplementation have on repeated bouts of the Wingate Anaerobic Test (WAnT).
Participants
For the purpose of this study, 65 students fi*om Lakehead University were 
recruited to perform a single, 30-s WAnT. All participants reported to the Lakehead 
University exercise physiology laboratory in clothing appropriate for vigorous exercise, 
having been previously instructed not to consume food or drink (except water) for 3 
hours, nor to smoke within 2 hours of testing. Furthermore, no heavy exercise during the 
24 hours leading up to testing was to be undertaken. Finally, all participants read a 
detailed cover letter (Appendix B) and signed an informed consent form (Appendix C) 
before any data collection occurred. Final approval by the Ethics Advisory Committee at 
Lakehead University was obtained before the commencement o f this study. Refer to 
Appendix A for a simplistic outline of the following methodology that was provided to the 
participants.
Single 30-s WAnT
Body weight, height, blood pressure, and heart rate were recorded, and a PAR-Q 
(Physical Activity Readiness Questionnaire) administered upon arrival at the laboratory. 
This was followed by five minutes o f slow, steady pace cycling, interspersed with bouts of
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moderate sprinting. Furthermore, participants engaged in 5-minutes of lower body 
stretching, which emphasized the quadriceps, hamstrings, and calf muscles and an 
additional 5-minute rest period was given. Therefore, a preparation period of 
approximately 15-minutes was allowed for each participant before any bout of cycle 
ergometry. At the conclusion of the 15-minute preparation period, each participant had 
the handlebars, toe-straps, and seat height adjusted. The test instrument was a Monark 
cycle ergometer (824 E with toe straps) modified with a preloaded weight pan that could 
be applied directly to the flywheel. Individual resistance was calculated at 0.1 kg/kg body 
weight and the corresponding weight added to the pan. Testing commenced by cycling 
with maximal exertion against minimal resistance for no longer then 5 seconds, as this 
allowed the highest revolutions of the flywheel to be achieved. A 5-s countdown was 
provided and at time "0", the weight pan was applied to the flywheel for a period of 30 
seconds and data recording began. The number of flywheel revolutions were recorded 
with an infi-ared counting system (Optosensor 2000 ^ )  and the computer software 
package EXTEND^ determined relative and absolute peak anaerobic power (PAP), 
relative and absolute mean anaerobic power (MAP) and rate of fatigue (RF). The 
researcher was not involved in the data collection of WAnT scores and from this point in 
time, the study was conducted in a double-blind fashion.
Selection of treatment and placebo groups
At a later date, participants were rank ordered from highest to lowest, according 
to relative peak anaerobic power (PAPr) scores obtained during the single 30-sWAnT.
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The purpose of this step was to construct a large distribution that represented PAPr 
scores, from which the final 20 participants were to be selected (see Figure 3). More 
specifically, 10 participants from both ends of this distribution were approached and 
requested to volunteer for the remainder of the study. Participants were selected in this 
manner due to the relationship that has been reported between power measurements 
during WAnT and muscle fiber type distribution (Bar-Or et al., 1980; Inbar et al., 1981; 
Kaczcowski et al., 1982; Froese and Houston, 1987). Unfortunately on the first day of 
data collection, one of the participants removed himself from the remainder of the study 
and the following four groups were constructed: 1) high WAnT with creatine (n = 5), 2) 
high WAnT with placebo (n = 5), 3) low WAnT with creatine (n = 5), and 4) low WAnT 
with placebo (n = 4)
Figure 3. Distribution and frequency o f PAPr scores  
(30-s WAnT) for original 6 5  participants
Î :
SW. Dev = 1.31 
Mean = 12.83 
N= 65.00
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Nutritional Assessment
Once participants were selected, they attended an information session in which all 
vital information related to their involvement in the study was presented, questions or 
concerns answered, and consent forms signed. The study began with participants 
maintaining a nutritional log (Appendix F) for 3 days before pre-supplementation muscle 
biopsies (days 1 through 3 of the study), and as well for a 3 day period before post­
supplementation muscle biopsies (days 8 through 10). Participants consumed their regular 
diet and meticulously recorded all food consumed. This information was entered into Diet 
Analysis Plus (Version 4.0), which allowed pre and post-supplementation protein intake to 
be calculated. If any significant differences were detected in protein consumption between 
pre and post-supplementation, then those participants would be removed fî om the study. 
As previously stated, creatine can be formed endogenously through the combination of 
three amino-acids (Murray, Granner, Mayes, and Rodwell, 1996) and therefore it was 
imperative that this factor be controlled.
Repeated bouts o f the WAnT
All 19 participants performed 5 repeated bouts of the WAnT on days 5 and 12 of 
the study. Each bout lasted 15-s in duration, with 45-s of active rest against a resistance 
of 0.075 kg/kg body weight. All other aspects of the repeated WAnT were identical to 
those previously describing the single 30-s WAnT within the methodology (page 33).
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Muscle Biopsies and Fiber Tvnc Determination
Pre and post-supplementation percutaneous muscle biopsies were obtained from 
the vastus lateralis muscle group according to the technique outlined by Bergstrom 
(1962). A medical doctor (Appendix D) using a 6 mm-biopsy needle, removed 
approximately 50-75 mg of tissue from each participant. Samples had all visible blood and 
connective tissue removed, oriented on a cork surface, fixed with OCT compound and 
then immediately frozen in 2-methylbutane, pre-cooled with liquid nitrogen (Brooke and 
Kaiser, 1970). Samples were then stored in an ultra-low freezer at approximately -80 °C 
until such time that analysis could occur. Muscle tissue stored upon cork was cut in serial 
sections at approximately -16° C, each 12 pm in thickness, and subjected to the myosin- 
ATPase staining technique after a 24 hour drying period (Brooke and Kaiser, 1970). Pre- 
incubation pH's o f4.30, 4.54, and 10.3 were utilized to achieve differentiation in 
identifying Type I, Ha, and Eh, muscle fibers for our specimens. The histochemical 
staining allowed fiber type composition to be calculated (% Type I, % Type II, % Type 
Ha, and % Type Ilb).
SuDPiementation
Participants within the creatine groups were supplied with 20 bags of creatine 
monohydrate plus a carbohydrate additive (dextrose powder). Therefore, each bag 
contained 5 g of creatine monohydrate (EAS pure creatine) and 2 g of dextrose powder 
that was consumed 4 times per day for 5 days, beginning on day 6 and continuing until day 
10 of the study. The placebo groups received the same number of supplements, with each 
bag containing 7 g of dextrose powder. No difference in appearance or flavour could be
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detected between the bags containing the treatment and placebo. All participants had been 
instructed to consume their supplements at regular intervals throughout the day, at least 2 
hours before or after a meal and/or exercise, in order to reduce the insulin response 
produced by feeding and exercise (Harris et al., 1992). Finally, participants recorded their 
nutritional intake on days 8-10 and returned to the laboratory on day 11 and 12, at which 
time post-supplementation muscle biopsies were taken and repeated bouts of the WAnT 
occurred. A questionnaire was provided on day 12 to all participants, which attempted to 
discover their level of compliance during the study (Appendix E).
Statistical Analysis
The design of the study was a 2 x 2 x 2 x 5  split-plot factorial ANOVA. More 
specifically, 2 (Time: pre and post) by 2 (Treatment: creatine or placebo) by 2 (WAnT: 
low or high) by 5 (Bouts: 1 to 5). The dependent measures during the five repeated bouts 
of the WAnT were relative and absolute PAP, relative and absolute MAP, and Fatigue 
Index (FI). To facilitate analysis, change scores were calculated for all dependent 
measures (pre minus post) during the five bouts. This resulted in 5 factorial ANOVA's 
being utilized to analyze the relationships between Treatment (main effect A), WAnT 
(main effect B), Bouts (main effect C), and the interaction effects of Treatment x WAnT, 
Treatment x Bouts, WAnT x Bouts, and Treatment x WAnT x Bouts. Furthermore, 
factorial ANOVA's were the statistical tests used to assess the effect of treatment on body 
weight, height, and protein intake. If needed, a Tukey*s HSD was utilized as the preferred 
test during any post-hoc analysis. In addition, bivariate correlation and Spearman’s rank- 
order correlation (rho) were performed with PAPr (30-s WAnT) and percent fiber types.
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An alpha level of p <0.05 was implemented for all test of significance and post-hoc 
analyses. Finally, all statistical analyses were performed by the SPSS statistical software 
package, version 8.0.




Muscle Biopsies and Fiber Tvoe Determination
With preincubation pH's o f4.30, 4.54, and 10.15, the myosin-ATPase staining 
technique (Brooke and Kaiser, 1970) resulted in the greatest differentiation in respect to 
Type L Ha, and lib muscle fibers for our specimens. It is important to demonstrate to the 
reader that the researchers were able to differentiate fiber types and determine fiber type 
composition (% Type I, % Type H, % Type Ha, and % Type lib). Figure 4 represents 
three serial sections (sections A, B, & C) of muscle fi*om a single participant. Section A 
(pH of 4.30) reveals that Type I muscle fibers were activated and therefore stained with a 
dark intensity, whereas Type II muscle fibers were inactivated and light in intensity 
(Brooke and Kaiser, 1970). The opposite occurs with a preincubation pH of 10.15 
(section C), with Type II fibers now being activated (dark intensity) and Type I fibers 
inactivated (light intensity). At a pH of 4.54 (section B) Type I fibers remain inactive and 
light in intensity, whereas Type II now differentiate into Type Ha fibers (light intensity) 
and nb fibers (grey intensity).
Group Characteristics
Once the groups were formed, it was important that the high and low groups were 
significantly different in respect to their PAPr scores recorded during the single 30-s 
WAnT. A 2 (Treatment; creatine or placebo) by 2 (WAnT: high or low) factorial 
ANOVA, revealed a significant main effect for WAnT (F (1,15) = 29.14, p<0.0001) as 
depicted in figure 5, with no other significant main or interaction effects being detected.
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This result indicates that our groups will most likely differ significantly as well in respect 
to percent Type H muscle fibers.
Figure 4- Ifistochemical stains using the myosin ATPase format with preincubations of (A) 
pH 4.3, (B) pH 4.54, and (C) pH 10.15 in serial sections o f the vastus lateralis muscle 
group.^ = Type I; = Type Ha; O =Type Ub.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Figure 5. Significant main effect for WAnT (fiigfi or lov^, 











É sl 11.8 IÉ
iUiUSpmf
high RAP & Cr Ugh RAP & Pb Low RAP & &  Low RAP & Ha
Treatment
42
^significantly difi&rent from low PAP with Cr and Pla, p<0.0001.
The next step then was to determine if any statistical relationships were evident 
between PAPr (30-s WAnT) and fiber type composition, specifically percent Type H 
muscle fibers. A bivariate correlation was first calculated, with PAPr as the predictor 
and percent Type II muscle fibers as the criterion variable. A positive, but weak 
correlation was detected between the two variables (r = 0.52, p<0.05) as depicted in 
figure 6.
A logical next step was to determine if the ranking of participants according to 
PAPr (30-s WAnT) and percent Type II muscle fibers were significantly related. This 
was accomplished by means of a Spearman rank-order correlation (rho) which revealed a 
positive monotonie relationship (rho = 0.61, p<0.01) between the same two variables 
(Table 15).
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Figure 6 . Scatterplot depicting PAPr (30-s WAnT) 
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Table 15. Comparison o f Rank-Ordering of Participants According to PAPr and percent
Participan
t
Rank of PAPr Rank of % Type II Participan
t
Rank of PAPr Rank of % Type H
1 11 3 11 11 18
2 1 9 12 18 14
3 19 19 13 11 17
4 15.5 15 14 13 12
5 14 6 15 3 7
6 5.5 1 16 2 4
7 9 8 17 7 5
8 8 11 18 17 16
9 4 10 19 5.5 2
10 10 15.5
Finally, a 2 (treatment; creatine or placebo) by 2 (WAnT: high or low) factorial 
ANOVA, with a dependent measure of percent Type II muscle fibers revealed only a 
significant main effect again for WAnT (F (1,15) = 12,83, p<0.01) as depicted in figure 
7. The significant correlation, Spearman’s rank-order correlation and the factorial
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ANOVA revealed that our “high and low Wingaters” according to PAPr scores obtained 
during the single 30-s WanT test, were also significantly different in respect to percent 
Type n  muscle fibers.
Figure 7 . Significant effect for WAnT (high or low),
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*significantly different from low PAP with Cr and Pla, p<0.01.
The same statistical procedures were utilized with percent Type Ua muscle fibers 
as the dependent measure. A non-significant correlation of r = 0.43 (p >0.05) was 
detected with PAPr scores (predictor) and percent Type Ha muscle fibers (criterion 
variables). The Spearman’s rank order correlation test revealed that the rankings of the 
participants according to PAPr and percent Type Da muscle fibers were significantly 
related (rho = 0.56, p<0.05). Finally, a 2 (treatment: creatine or placebo) by 2 (WAnT: 
high or low) factorial ANOVA with a dependent measure of percent Type Da muscle
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fibers, revealed a significant main effect only for WAnT (F (1,15) = 7.42, p<0.05) as 
depicted in figure 8.
Percent Type lib muscle fibers was also analyzed as the dependent measure with 
the aforementioned statistical tests. A non-significant correlation of r = 0.22 (p<0.05) 
and a Spearman’s rank order correlation of rho = 0.21 (p<0.05) was detected between 
PAPr and percent Type lib muscle fibers. Furthermore, a 2 (treatment: creatine or 
placebo) by 2 (WAnT: high or low) factorial ANOVA with a dependent measure of 
percent Type Ilb muscle fibers, revealed a non-significant main effect again for WAnT (F 
(1,15) = 7.42, p<0.05) as depicted in figure 9. No other significant main or interaction 
effects were detected.
Figure 8. Significant main effect for WAnT (high or lov\ ,̂ 
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"significantly different fi’om low PAP with Cr and Pla, p<0.05.
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Figure 9. Nonsignificant effect for WAnT (high or lovŷ , 
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Anthropometric and Nutritional Analysis Data
Table 16 displays the physical characteristics, age, and protein intake and urinary 
volume at pre and post-supplementation. Creatine supplementation has been reported to 
significantly increase body mass and therefore a 2 (Time: pre or post) by 2 (WAnT: high 
or low) by 2 (Treatment: creatine or placebo) split-plot Factorial ANOVA, with body 
mass as the dependent measure was performed. Only a significant main effect for Time 
(F (1,15) = 7.1, p<0.05) was detected (Appendix G).
As mentioned within the methodology, pre-supplementation and post­
supplementation nutritional assessments were used to control for protein intake. These 
data were analyzed once again by a 2 (Time: pre or post) by 2 (WAnT: high or low) by 2 
(Treatment: creatine or placebo) split-plot Factorial ANOVA with protein intake as the 
dependent measure. No significant main or interaction effects were found (Appendix G).












Creatine 21.30 178.67 82.97 83.83 95.77 94.67
n =  10 ±1.5 ±8.1 ±16.5 ±16.5 ±12.7 ±13.2
Placebo 22.20 180.59 85.34 85.72 99.44 96.38
n = 9 ±2.2 ±7.6 ±11.6 ±12.3 ±19.4 ±24.6
G r . # l 21.60 177.80 78.94 79.90 98.48 96.24
n = 5 ±0.9 ±3.7 ±13.5 ±13.7 ±13.8 ±13.0
Or. # 2 23.20 184.35 82.82 83.00 95.06 89.72
n = 5 ±2.6 ±2.5 ±2.4 ±2.4 ±18.8 ±29.6
Or.# 3 21.00 179.54 87.00 87.76 93.04 93.10
n = 5 ±2.0 ±11.4 ±19.8 ±19.7 ±12.3 ±14.7
Gr.#4 21.00 175.87 88.50 89.13 104.91 104.70
n = 4 ±0.8 ±10.1 ±18.2 ±19.1 ±21.5 ±16.7
Gr. #1 = creatine and high WAnT, Gr. #  2 = placebo and high WAnT, Gr. #  3 = creatine and low 
WAnT, and Gr. #  4 = placebo and low WAnT, NA = not applicable.
Repeated Bouts of the WAnT
Tables 17-20 displays power measurements recorded during each of the 5 repeated 
bouts of the WAnT. Each table represents one group and allows for comparison of 
performance at pre and post-supplementation. Statistical output is provided for each of 
the five dependent variables, expressed as change scores in Appendix G. There were no 
significant main or interaction effects (p >0.05) for any of the five dependent measures 
when analyzed by means of 2 (Treatment: creatine or placebo) by 2 (WAnT: high or low) 
by 5 (Bouts: 1 to 5) factorial ANOVA's.






































Table 17 Performance data for 5 repeated bouts of the WAnT (Group #1).
PAPr (Watts/kg) PAPa (Watts) MAPr (Watts/kg) MAPa (Watts) FI (Watts)





B o u t#1 Pre 10.8 0.4 855 165.0 9.6 0.3 757 120.9 21.8 8.0
Post 11.0 0.3 880 155.4 9.6 0.7 760 108.2 26.8 11.4
Bout #2 Pre 9,5 0.4 749 122.9 7.9 0.3 625 102.1 30.0 3.7
Post 9.7 0.5 778 158.6 7.9 0.3 637 118.6 33.2 4.7
Bout #3 Pre 8.1 0.7 638 119.5 6.6 0.5 525 88.3 30.8 3.7
Post 8.3 0.7 664 146.3 6.6 0.5 531 119.4 35.6 4.0
Bout #4 Pre 6.9 0,9 548 141.3 5.6 0.5 450 108.9 30.8 8.1
Post 7.4 0.8 597 142.4 5.8 0.5 469 111.0 37.4 5.0
Bout #5 Pre 6.6 0.9 523 137.6 5.3 0.6 424 105.1 32.2 6.7





































PAPr (Watts/kg) PAPa (Watts) MAPr (Watts/kg) MAPa (Watts) FI (Watts)





B out #1 Pre 10.6 0.6 883 67.0 9.5 0.2 787 23.3 19.0 8.2
Post 10.7 0.4 889 37.4 9.5 0.3 789 35.7 21.0 3.4
B out #2 Pre 9.7 0.6 801 42.7 8.1 0.4 654 62.1 28.8 3.2
Post 9.6 0.3 795 19.6 8.1 0.5 671 47.7 28.6 6.8
Bout #3 Pre 8.6 0.9 716 79.4 6.9 0.8 578 64.6 34.0 6.8
Post 8.67 1.0 718 79.4 7.0 0.9 581 74.0 34.0 3.2
Bout #4 Pre 7.9 1.3 659 99.7 6.3 0.9 522 76.3 36.0 3.2
Post 7.9 1.0 661 81.7 6.4 1.0 532 77.4 35.0 2.7
Bout #5 Pre 7.6 1.3 624 112.5 6.1 1.0 503 87,8 33.5 5.7





































PAPr (Watts/kg) PAPa (Watts) MAPr (Watts/kg) MAPa (Watts) FI (Watts)




Bout #1 Pre 10.3 0.5 890 206.2 9.2 0.6 790 149,3 20.0 8.2
Post 10.2 0.6 893 187.1 9.1 0.6 787 144.1 23.2 7.3
Bout #2 Pre 9.3 0.8 801 149.4 7.8 0.7 673 117.3 29.6 5.0
Post 9.6 0.5 833 158.5 7.8 0.7 672 123.1 34.2 6.6
Bout n Pre 8.7 0.5 745 145.6 6.7 0.5 583 116.6 38.4 6.4
Post 8.3 0.5 722 127.2 6.6 0.7 571 96.4 37.0 7.1
Bout §4 Pre 7.6 0.4 667 171.6 5.8 0.3 508 112.9 41.0 5.2
Post 7.4 0.6 645 126.4 5.8 0.5 505 96.3 39.2 4.9
Bout #5 Pre 6.9 0.3 604 149.1 5.5 0.4 472 92.8 37.6 4.9









































Table 20. Performance data for 5 repeated bouts o f the WAnT (Group #4).
PAPr (Watts/kg) PAPa (Watts) MAPr (Watts/kg) MAPa (Watts) FI (Watts)





Bout #1 Pre 10.6 0.6 949 237.4 9.5 0.5 848 219.2 20.8 3.5
Post 10.4 1.2 919 183.8 8.9 0.7 789 145.6 25.5 6.8
Bout #2 Pre 9.4 0.7 795 123.9 7.9 0.4 705 176,2 28.8 8,8
Post 9.3 0.7 823 144.8 7.5 0.8 656 95.6 36.0 8.3
Bout #3 Pre 8.4 0.6 711 130.5 6.9 0.4 611 153.4 33.5 7.0
Post 8.1 0.4 722 154.7 6.5 0.8 575 94.8 34.3 12.5
Bout #4 Pre 7.7 0.6 638 143.9 6.1 0.2 545 122.9 38,5 6.9
Post 7.6 0.3 678 133.7 5.9 0.7 517 77.5 40.5 12.9
Bout #5 Pre 7.2 0.7 595 138.6 5.7 0.2 506 97.67 38.5 11.4





It is important to remember that originally sixty-five participants performed a 
single 30-s WAnT, and PAPr scores were rank-ordered fi’om highest to lowest. Since the 
ten participants with the highest and lowest PAPr scores did not all volunteer to partake in 
the remainder of the study, it was essential to test to see if the "high and low" WAnT 
groups were in fact significantly different in respect to PAPr scores obtained during the 
single 30-s WAnT. It was apparent that the 10 participants within the high group had 
higher PAPr scores, regardless of treatment (figure 5). As previously mentioned within 
the methodology, an essential assumption of this study was that participants with higher 
PAPr scores obtained during the single 30-s WAnT would possess higher percentages of 
Type n  muscle fibers (Bar-Or et al., 1980; Inbar, Kaiser, and Tesch, 1981; Kaczcowski et 
al., 1982; Froese and Houston, 1987). In other words, groups were formed according to 
exercise performance in the hopes that the high WAnT groups would also possess a higher 
percentage of Type II muscle fibers than the low WAnT groups.
One of the key findings of this study was the positive relationship between muscle 
fiber type composition, when expressed as percent Type II muscle fibers and PAPr (W • 
kg‘‘) during the single WAnT. This conclusion was based on the following information. 
Firstly, bivariate correlation analysis revealed that percent Type II muscle fibers 
(predictor) and PAPr (criterion) were significantly correlated (figure 6). However, the 
small r of 0.52 reveals that the predictor variable was only capable of explaining 27% (r̂  =
0.27) of the variance seen in the criterion variable. Furthermore, a Spearman’s rank-order
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correlation was used to see if the participants would hold their ranks. It was expected that 
those participants with high rankings according to PAPr (predictor) would also have 
correspondingly high rankings for percent Type II muscle fibers (criterion). The positive 
monotonie relationship (R = 0.611, p<0.01) between the variables revealed that there was 
a significant relationship between the ranking of participants according to the two 
variables. The data fi'om this study demonstrates a statistically significant, but weak 
relationship in the ranking of participants according to PAPr and percent Type II muscle 
fibers. More specifically, not all participants with high PAPr scores possessed high 
percentages of Type II muscle fibers. Finally, since the participants actual fiber 
composition was calculated (% Type I, % Type H, % Type Ha and % Type Ilb) the 
researcher could test to see if the groups were also significantly different in this respect. A 
2 x 2  factorial ANOVA revealed a significant main effect for WAnT, in which the high 
PAPr group had significantly higher values for percent Type II muscle fibers, regardless of 
treatment (figure 7). These findings were essential to the study design as they revealed 
that although participants were grouped according to PAPr scores obtained during the 
single 30-s WAnT, the groups also differed in fiber type composition, when expressed as 
percent Type II muscle fibers.
As stated in the results section, the same statistical procedures were performed 
with the percent Type Ila and Ilb muscle fibers as the dependent measure. Although a 
significant bivariate regression and factorial ANOVA were detected with percent Type Ha 
muscle fibers, the study focused on Type II muscle fibers since all three statistical analyses 
were significant and to a greater degree. No significant relationships were detected with 
percent Type Db as the dependent measure. For the purpose of this study however.
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participants with higher PAPr scores obtained during the single 30-s WAnT possessed 
higher percentages o f type II muscle fibers.
Repeated Bouts o f the WAnT
The major finding of this study, as related to the statement of the problem, was 
that 5 days of creatine supplementation (4 x 20g/day) had no detectable effect on 5 
repeated bouts o f the WAnT (15-s in duration against a resistance o f0.075 kg, with 45-s 
rest periods), regardless o f how participants were classified for the 30-s WAnT (high or 
low PAPr). This finding was unexpected since most research involving repeated bouts of 
high intensity exercise support creatine supplementation as having an ergogenic effect 
(Balsom et al., 1993 & 1995; Birch et al., 1994; Casey, et al., 1996; Dawson et al., 1995; 
Earnest et al., 1995; Greenhafif et al., 1993 & 1994; Kirksey et al., 1997; Lemon et al., 
1995; Schneider et al., 1997; Vandenberghe et al. (as cited in Williams and Brach, 1998); 
Volek et al., 1997; Ziegenfuss, Lemon, Rogers, Ross, and Yarasheski, 1997). In fact, 
Williams and Branch (1998) reviewed 17 articles related to creatine supplementation and 
cycle ergometry, and stated that eleven of those articles reported creatine as being 
beneficial to performance (25% ± 29% improvement) and only five failing to report 
creatine has being beneficial to performance.
It was expected that participants with high and low WAnT scores, and 
supplemented with placebo (groups #2 and # 4 respectively) would have no significant 
change in performance fi'om pre to post-supplementation. It was also expected that those 
with high and low WAnT scores who received creatine (groups #1 and #3 respectively) 
would show an improvement in performance, with the greatest effect seen in group #1
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(high WAnT and creatine). The hypothesis that high PAPr scores and creatine 
supplementation would result in the greatest improvement in performance was based on 
the following. Firstly, it has been proposed that higher intramuscular creatine stores might 
facilitate phosphocreatine resynthesis during the recovery phase of repeated bouts o f high 
intensity exercise (Greenhafif et al., 1994). Secondly, phosphocreatine has been shown to 
be an effective buffer for H+ and would restrict the formation of adenosinediphosphate, 
the starting point for adenine nucleotide degradation (Greenhafif 1999 et al., 1993). In 
addition (Tesch et al., 1989; Soderlund et al., 1992) have reported that Type II muscle 
fibers store and utilize significantly more phosphocreatine during intermittent, high 
intensity exercise than do Type I muscle fibers and therefore. Type II muscle fibers may 
also uptake or retain more of the supplemental creatine than Type I muscle fibers. Finally, 
it is important to recall that the high and low groups, according to PAPr scores obtained 
during the single 30-s WAnT were significantly different in respect to fiber type 
composition (percent Type II muscle fibers).
Based on the information present within the previous paragraph, it was 
hypothesized that Type II muscle fibers would uptake more of the supplemental creatine, 
resulting in greater ATP and phosphocreatine resynthesis. Therefore group #1, with a 
higher a percentage of Type II muscle fibers and receiving creatine supplementation, 
would experience the greatest uptake of creatine with a consequent improvement in 
performance. To address this question, it would be necessary to obtain pre and post­
supplementation muscle samples, determine fiber type distribution, and analyze for 
creatine, phosphocreatine, and adenosinetriphosphate levels. However in this study, we 
were restricted to a determination of fiber type distribution only, but a review of previous
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studies reveal that creatine supplementation should have raised total creatine levels within 
muscle (Greenhafif et al., 1994; Harris et al., 1992; Hultman et al., 1996). As previously 
reported, no significant main or interaction effects were detected for any of the dependent 
measures across all five bouts of the WAnT (Appendix G). Theoretically, creatine 
supplementation could be effective after numerous bouts of high intensity exercise. This 
prediction was based on the work of Balsom et al (1995) who had participants perform 
five bouts of maximal cycling at 140 revolutions/minute, against a resistance that produced 
maximum work and found that phosphocreatine levels were only significantly higher for 
the treatment group after the fifth bout of high intensity cycle performance. Consequently, 
one would expect performance only to improve after creatine supplementation has an 
effect at the metabolic level (i.e. increased levels of phosphocreatine).
An improvement in performance for PAP and MAP (absolute and relative) would 
be indicated by negative change scores (pre minus post) and would represent greater 
scores being achieved after five days of creatine supplementation. It was expected that 
group #1, with a higher percentage of Type II muscle fibers and having received creatine 
supplementation, would have significantly greater, negative change score values (pre 
minus post) for PAPa, PAPr, MAPa, and MAPr than the other three groups. If this 
prediction had been true, a graph similar to figure 10 might have resulted. In reviewing 
figure 10, one could expect the placebo groups (#2 and #4) to show no improvement in 
performance and have lines that are basically above the "0.0" mark on the ordinate or 
show no consistent pattern of negative change scores. The treatment groups however (#1 
and #3), might have lines that begin around the "0.0" mark on the ordinate, but begin to
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
57
Steadily slope downwards towards bout # 5, with ever increasing negative change scores. 
Figures 11-14 show the actual outcomes for the four groups in regards to change scores 
for PAP and MAP (relative and absolute). As predicted, the placebo groups showed no 
improvement in performance. However, the creatine groups also showed no signs of 
improvement in performance as the lines undulated in an unpredictable maimer.
Figure 10. Line graph depicting eiqsected outcome of treatment 
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Figure 11. Line graph depicting nonsignficant effect of 
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Figure 12. Line graph depicting nonsignifican effect of 
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Figure 13. Line graph depicting nonsignificant effect of 
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Figure 14. Line graph depicting nonsignificant effect of 
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The last dependent measure of interest was the fatigue index (FI), which 
examined the degree of power drop-off during the WAnT (Inbar, Bar-Or and Skinner, 
1996). Based on the information within the first paragraph on page 55, it was also 
anticipated that group #1, with a higher percentage of Type II muscle fibers and 
supplemented with creatine, would experience a greater ability to maintain power output 
during the WAnT (Balsom et al., 1995). Improvements in performance for FI would be 
indicated by positive, rather than the negative change scores as previously mentioned for 
MAP and PAP. Therefore, change scores for FI (pre minus post) would be significantly 
greater for group #1 than the other three groups and again, it was hypothesized that only 
after several bouts of high intensity exercise would the benefits of creatine 
supplementation be detected (figure 15).
Figure 15. Line graph depicting expected outcome 
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However, the actual outcome again was not similar to the expected outcome as 
evidenced figure 16. All four groups produced lines that were random in nature and 
displayed no maintenance of power across all five bouts (figure 16).
Figure 16. Line graph depicting nonsignificant effect of 
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The results obtained in this study are in agreement with only a few of the studies 
that have investigated creatine supplementation on repeated bouts of high intensity 
exercise. Barnett, Hinds, and Jenkins (1996) reported that 20g o f creatine/day for 4 days 
had no effect on peak power or mean power output (absolute or relative) during repeated 
sprint cycle performance (7 x 10 bouts with 30-s of passive rest between bouts 1-5, and 
5-min between bouts 5-7), with a gear ratio eliciting 8.87 rev/pedal crank revolution. 
These researchers concluded that either creatine supplementation failed to significantly 
raise muscle creatine concentration or creatine concentration was significantly increased.
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but performance during 7 x 10-s cycle sprints was not affect. Moreover, Gonzalez de 
Suso et al. (as cited in Williams and Branch, 1998) used a randomized double-blind, 
placebo-control, cross-over design to examine creatine supplementation (21 g/day for 14 
days) on 7 X 7-s bouts o f cycle sprinting. The [PCr]/[(3-ATP] ratio increased in both 
groups, but performance results were equivocal, with a 7% increase in peak power 
detected only when placebo was taken before creatine. The length of the washout period 
was not provided and consequently the authors felt the time period may have been 
insufGcient and that a treatment effect could have been overlooked (V ^am s and Branch, 
1998). Thirdly, McKenna, Morton, Selig, and Snow (1999) revealed that six doses of 5g 
of creatine plus 5g of dextrose powder for 5 days significantly raised resting 
concentrations of creatine, phosphocreatine, and total creatine (creatine + 
phosphocreatine), but had no effect on five bouts of intermittent maximal cycling. The 
authors suggested that a  placebo effect was responsible for masking the true treatment 
effect of creatine supplementation. Febbraio et al. (1995) and Redondo et al. (1996) also 
reported that creatine supplementation was ineffective as an ergogenic aid for repeated 
bouts of intermittent maximal exercise. However, the length and number of bouts used in 
their studies were not comparable to the present investigation.
In this study, there are several reasons why creatine supplementation did not 
produce an ergogenic effect. First, it has been well established that ingestion of 
approximately 5g of creatine in solution will raise plasma creatine concentration fi*om -40 
pmol/1 to 600-800 pmol/1 within 1 hour (Green et al., 1996; Harris et al., 1992). 
Furthermore, ingesting 20 g/day for 5 days can increase intramuscular creatine levels by 
20%, of which 20% can be found as phosphocreatine (Greenhaff et al., 1994; Harris et al..
Reproduced with permission o fthe copyright owner. Further reproduction prohibited without permission.
63
1992). Based on previous work (Greenhaff et al., 1994; Harris et al., 1992; Hultman et 
al., 1996) we would assume that our creatine supplementation protocol (4 x 5g of creatine 
+ 2 g of dextrose powder/day for 5 days) would have resulted in similar intramuscular 
phosphagen levels, but unfortunately muscle total creatine levels (creatine + 
phosphocreatine) were not measured. However, the possibility exists that our 
supplementation protocol did not elevate resting intramuscular phosphagen levels to the 
point needed to meet the demands of five repeated bouts of the WAnT, and consequently, 
no improvement in performance would be expected. This is highly unlikely, since a 
majority of research involving creatine supplementation with repeated bouts of 
intermittent, high-mtensity exercise, have reported an ergogenic effect (V^lliams and 
Branch, 1998).
Having participants perform 5 x 15-s repeated bouts of WAnT, with 45-s of active 
rest between bouts, resulted in a work to rest ratio of 1:3. With a half recovery time of 
phospocreatine stores at 30-s (McArdle, Katch and Katch, 1999) our participants had 
sufBcient time to restore at least 50% of their phosphocreatine levels in preparation for the 
next bout of exercise. As the bouts progress however, and these participants not being 
highly trained, the formation of lactate within the muscle might have caused fatigue and 
account somewhat for the performance results. However (Christensen, Hedman, and 
Saltin, 1960) have shown that with 15-s work and only 30-s rest (1:2 work to rest ratio), 
lactate levels were only at 1.8 mmol. It is also possible that 5 bouts of the WAnT did not 
produce a true “state of fatigue" and that additional bouts might have resulted in our 
expected outcome. That is group # 1, high PAPr with creatine supplementation would 
have experienced the greatest improvement in performance as the bouts progressed.
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However, our participants were not highly trained and most would have been unable to 
perform even one additional bout.
Another possible explanation for our unexpected outcomes could be due to the 
sample sizes per group (i.e. per cell). Although an overall sample size of nineteen was 
similar with previous studies, the research design employed, a 2 (Time; pre and post) by 2 
(Treatment; creatine or placebo) by 2 (WAnT; low or high) by 5 (Bouts; 1 to 5) split-plot 
factorial ANOVA, was a limiting factor. DiekhofT (1992) stated that sample sizes per cell 
(group) should be approximately equal, with approximately 10 -15 cases (i.e. participants) 
per cell for a factorial ANOVA. The placement of the participants into four groups was 
necessary if the research question was to be answered, and therefore, small sample sizes 
per group (n=5 for three groups and n= 4 for one group) resulted. This was significant 
because in a group of 4-5 participants per cell, a single individual could contribute 20% - 
25% of the variance in any of the change scores (dependent measure), in comparison to 
6.67% - 10% if sample sizes had been 15 or 10 participants per cell. Change scores fi-om 
a single participant would yield too much influence per cell mean, which could result in 
statistical non-significance for the factorial ANOVAs. One participant within the 
treatment group could have been a "non-responder" to creatine supplementation, and as a 
result could mask the ergogenic effect that might have been present. This is a distinct 
possibility, as it has been estimated that nearly 30% of those who undergo creatine 
supplementation do not experience significant increases in creatine and phosphocreatine 
levels (Greenhaff 1997). The reasons for this are unclear, but with small sample sizes per 
cell, a single "non-responder" within the creatine groups could easily affect the data in 
such a manner that the treatment would appear to have no ergogenic effect on repeated
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bouts of the WAnT. In a similar manner, the placebo groups could have masked the 
ergogenic effect o f creatine supplementation, by a single participant experiencing the 
common "placebo effect".
A possible situation, although unlikely, was proposed by McKenna et al. (1999) to 
explain the results of their study in which they proposed that a learning effect could have 
occurred only for the placebo groups, and a creatine-induced ergogenic effect only within 
the creatine groups. This again could have negated the ergogenic effect o f creatine 
supplementation, but the likelihood of this occurrence seems negligible.
As previously mentioned, exogenous creatine can be consumed in a supplemental 
or natural form. Throughout the study design, supplemental sources of creatine were 
monitored, as were natural sources by means of pre and post-supplementation nutritional 
analyzes. No significant main or interaction effects were detected.
Finally, a limitation of this study was the reliance on the manufacturer (EAS) 
providing high quality creatine monohydrate. It should be obvious that if the product was 
not pure creatine, no ergogenic effect would be detected as no “treatment" would have 
been administered to the creatine groups. The likelihood of creatine not being high quality 
is highly unlikely, but reported to cover all possibilities.
Body Mass
Numerous articles have reported increases in body mass after creatine 
supplementation (Balsom et al., 1993; Dawson et al., 1995; and Earnest et al., 1995;
Godly and Yates, 1997; Goldberg and Bechtel, 1997;). It was expected that a significant 
interaction effect for Time x Treatment x WAnT would have been detected, in which
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group # 1 (high PAPr + creatine) would have gained weight after S days of 
supplementation. However, both groups gained a significant amount of weight, ftom pre 
to post-supplementation (main effect for Time). Increases in body mass with creatine 
supplementation are thought to be the result of water retention and greater lean body 
mass. No measurement of water retention or lean body mass was taken and therefore it is 
unclear if these variables contributed to the significant increase in body mass. Increases in 
lean body mass are thought to be greatest in those who have low initial intra-muscular 
creatine concentrations (Balsom et al., 1993; Delanghe et al., 1989; Harris et al., 1992), 
but this could not be confirmed since muscle creatine analysis was not performed.
To summarize, 20 g of supplemental creatine for. 5 days had no effect on 5 
repeated bouts of the WAnT, regardless of participants possessing a high or low 
percentage of Type II muscle fibers. The most likely explanation for this finding was that 
the number of participants per group was inadequate, which result in any one participant 
contributing too much influence towards the data. On a more positive note, we found a 
positive correlation (r = 0.52, p<0.05) between PAPr (30-s WAnT) and percent Type II 
muscle fibers, which corresponds to previous research. Furthermore, we were able to 
form the groups according to PAPr (30-s WAnT), ensuring that the “high and low 
Wingaters” were significantly dififerent from each other, and based on our prediction, the 
groups were also significantly dififerent in respect to percent Type n  muscle fibers.
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CHAPTER 6
SUMMARY, CONCLUSIONS, AND RECOMMENDATIONS
Summary
This study examined the influence of fiber type distribution and creatine 
supplementation on five repeated bouts of the Wingate anaerobic test (WAnT). Sixty-five 
participants performed a single 30-s WAnT and were ranked-ordered fiom highest to 
lowest, according to relative peak anaerobic power (PAPr). Nineteen participants 
volunteered in such a maimer that ten (n=10) represented high PAPr scores and nine (n=9) 
low PAPr. This was undertaken with the assumption that PAPr scores obtained during a 
single 30-s WAnT would be positively related to fiber type distribution, expressed as 
percent type II muscle fibers. Fortunately, muscle fiber typing revealed a positive, but 
weak relationship between peak anaerobic scores (relative) obtained during the single 30-s 
WAnT and percent type II muscle fibers (r = 0.52, p<0.05). This means that although our 
groups were based on PAPr scores, the groupings (1. high WAnT with creatine, 2. high 
WAnT with placebo, 3. low WAnT with creatine, and 4. low WAnT with placebo) also 
reflected muscle fiber type distribution (% type II). Five repeated bouts of the WAnT 
were performed, each lasting 15-s, against a resistance o f0.075 kg/kg body weight and 
with 45-s of active rest between each bout. Supplementation occurred for five 
consecutive days, with groups # 1 and #3 receiving the treatment (4 x 5g of creatine + 2g 
of dextrose powder) and groups # 2 and # 4 the placebo (4 x 7g of dextrose powder).
Peak anaerobic power (absolute and relative), mean anaerobic power (absolute and 
relative) and rate of fatigue (fatigue index) were recorded during each bout. Statistical 
analysis was comprised of a series o f 2 x 2 x 2 x 5  split-plot factorial ANOVA's, one for
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each of the 5 dependent measures (change scores). Body mass was also tested for the 
effect of creatine supplementation by means of factorial ANOVA's. All four groups 
experienced a significant increase in body mass from pre to post-supplementation, 
regardless o f Treatment or WAnT. No significant main or interaction effects were 
detected with protein intake as the dependent measure.
Conclusions
The following conclusions have been reached from the results and discussion of 
this investigation;
1. No significant main or interaction effects for change scores on any o f the 5 
dependent measures, regardless o f WAnT (high or low PAPr), treatment (creatine or 
placebo), and bouts (# 1- # 5) were detected.
2. PAPr scores obtained during the single 30-s WAnT were statistically related to 
fiber type distribution, when expressed as percent type H and Ha.
3. Body mass increased from pre to post-supplementation, regardless o f whether 
participants were high or low (WAnT) and receiving creatine or placebo (Treatment).
Recommendations
1. It is essential that cell sizes be increased to include approximately 10-15 
participants.
2. Creatine and phosphocreatine uptake must be measured with blood and muscle 
samples.
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3. If time and money allow, participants should be grouped based on fiber type 
distribution, instead of relying on the relationship between PAPr scores obtained during a 
single 30-s WAnT and percent type II muscle fibers.
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“The Influence of Type II Muscle Fibers on the Uptake of Creatine and its Effect on




I would like to begin by thanking-you for volunteering to be a participant in this 
research study. Furthermore, feel free to approach me at anytime if you have any questions 
or concerns related to this research study.
The intent of this research study is to investigate the influence of fiber type 
distribution on the uptake of supplemental creatine and its effect on repeated bouts of 
maximal cycle ergometry. More specifically, do those participants with a higher 
percentage of type II muscle fibers uptake more creatine, and if so, do those same 
participants demonstrate a greater significant improvement in repeated bouts of cycle 
ergometry.
A simple and noninvasive means of grouping participants according to muscle fiber 
type distribution is to record peak anaerobic power (PAP) scores achieved during a single 
30 second Wingate test. In other words, high and low PAP scores are correlated with a 
higher and lower percentage of type II muscle fibers respectively.
The purpose of SECTION A in the study is to collect PAP scores from 150-200 
undergraduate, male kinesiology students and therefore participants will be asked to 
perform a single 30 second Wingate test. Following this test, you may experience a brief 
period of muscular fatigue in your legs and possibly nausea. You will be required to 
refrain from ingesting food, caffeine, and/or alcohol for three hours prior to the initiation 
of testing.
From these participants, 40-50 will be asked to volunteer for the study based on 
their PAP scores and those individuals not approached will have fulfilled their role in this 
study.
As a volunteer, you have the right to refuse any test and to withdraw from study at 
any time. All information collected for the purpose of this research will remain confidential 
through the use of a coding system. No reference to any participants will be made in an 
any report of the results. The data will be stored by Marc Poirier and by Dr. Norman 
LaVoie within the Faculty of Kinesiology at Lakehead University for a period of seven
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years. The findings of the study will be made available to you at your request upon 
completion of the project.
You also be required to fill out a modified Physical Activity Readiness 
Questionnaire (PAR-Q) with one additional question related to local anesthetics, as a 
subject you answer ves to any of the questions on the modified PAR-Q, your participation 
in this study will not be needed.
If you have any questions concerning the study, I may be reached by phone at 




Advisor: Dr. Norman LaVoie
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
85
March, 2000
SECTION B (this section pertains oniy to the final 20-25 subjects)
Based upon your PAP score, you have been asked to volunteer for the remainder 
of this study. As a reminder, the purpose of this study is to investigate the influence of 
fiber type distribution on the uptake of supplemental creatine and its effect on repeated 
bouts of maximal cycle ergometry. The following paragraphs will outline what is expected 
of each participant for the remainder of the study.
You will be required to record your daily nutritional intake for 3 days on 
two separate occasions. That is, everything that you consume (food and drink) will be 
written down in a logbook according the procedures outlined in the information session.
You will also be required to provide, on two separate occasions, urine, blood, and 
muscle samples. The urine sample requires that you collect all urine for a 24 hour period 
and return the sample to the laboratory at the specified time. In donating blood, you will 
be asked to allow a phlebotomist to withdraw 5 ml of venous blood and can expect 
minimal discomfort with this procedure.
The muscle sample technique was reintroduced by Bergstrom in 1962 and has been 
used extensively in the area of biochemistry since that time. A medical doctor will, under 
an aseptic technique, remove a 50-75 mg muscle sample (one-tenth the size of a sugar 
cube) fi-om a small, 1 cm incision fi-om the vastus lateralis muscle group using a 6 mm 
biopsy needle under local anesthetic (2-3 ml of xylocaine hydrochloride). There exist the 
possibility of a hypersensitivity reaction to the local anesthetic, in which slight discomfort 
could persist for 1 to 2 hours following the procedure. Furthermore, there exist the 
possibility of slight muscle soreness for few days following the muscle biopsy procedure.
In addition, if samples are taken in a highly iimervated and vascularized area, there exist 
the possibility of nerve damage and arterial bleeding. However, the area that will be 
sampled in this study reduces the probability to near nonexistence.
You also be required to perform, on two separate occasions, 5 repeated bouts of 
cycle ergometry. More specifically, each bout will be 15 seconds in duration with an active 
rest period of 45 seconds between bouts. Following this test, you may experience a brief 
period of muscular fatigue in your legs and possibly nausea. You will also be required to 
refi-ain fi-om ingesting food, caffeine, and/or alcohol for three hours prior to the initiation 
of testing.
As previously stated, you will be required, on two separate occasions, to record 
your nutritional intake, to provide urine, blood and muscle samples, and to perform 
repeated bouts of cycle ergometry. In the time separating those occasions, you will receive 
either 4 doses of 5 grams of creatine monohydrate + 2 grams of dextrose powder for a 
period of 7 days (treatment) or 4 doses of 7 grams of Dextrose (simple sugar) for a period 
of 5 days (placebo). The only consistently reported side-effect of short and long-term
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creatine supplementation in peer reviewed publications, has been an increase of 0.5 kg - 
2.4 kg in body weight. Furthermore there have been unpublished, and therefore ancedotal 
reports of creatine supplementation resulting in muscle cramping and spasms during high 
intense exercise.
The potential benefit of this study is to better understand who would benefit most 
fi-om creatine supplementation. Creatine monohydrate is one of the most widely used 
nutritional supplements in the past decade and the obtained data should provide answers 
related to whether or not fiber type composition influences the uptake of creatine, and 
subsequently effect repeated bouts o f cycle ergometry.
As a volunteer, you have the right to refuse any test and to withdraw fi-om the 
study at any time. All information <x)llected for the purpose of this research will remain 
confidential through the use o f a <x)ding system. No reference to any participants will be 
made an any report of the results. The data will be stored by Marc Poirier and by Dr. 
Norman Lavoie within the Faculty of Kinesiology for a period of seven years. The findings 
of the study will be made available to you at your request upon completion of the project.
If you have any questions cx>nceming the study, I may be reached by phone at 




Advisor: Dr. Norman LaVoie
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Appendix C
“The Influence of Type II Muscle Fibers on the Uptake of Creatine and its Effect on
Repeated Bouts of Cycle Ergometry”
October, 1999 
SECTION A:
I _______________________________ , agree to perform a single 30 second bout of
cycle ergometry as part of the subject selection process for the research study being 
conducted by f ^ c  Poirier, a graduate student within the faculty of Kinesiology at 
Lakehead University. I sign this with the knowledge that I may experience a brief period 
of muscular fatigue in my legs and nausea following the test.
I have read and understand SECTION A of the cover letter, which outlines that 
the purpose of this step in the study is to collect peak anaerobic power (PAP) scores fi-om 
150-200 undergraduate, male kinesiology students at Lakehead University. Furthermore, I 
understand that the final group o f40-50 participants will be asked to volunteer for the 
study based on their PAP scores and that those individuals not approached will have 
fulfilled their role in this study.
Signature of Participant Date
Signature of Witness Date
SECTION B
agree to participate in the remainder of the
study outlined in SECTION B of the cover letter. That is, to investigate the influence of 
muscle fiber type distribution on the uptake of supplemental creatine and its effect on 
repeated bouts of maximal cycle ergometry..
I _______________________________ , furthermore agree to record all my daily
nutritional intake for 3 days on two separate occasions. That is, everything that I consume 
(food and drink) will be written down in a logbook according the procedures outlined in 
the information session.
I _______________________________ , agree to provide, on two separate occasions.
urine, blood, and muscle samples as outlined in the accompanying cover letter. I sign this
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form with the knowledge that I may experience some minor discomfort when blood and 
muscle samples are taken.
I _______________________________ , also agree to perform, on two separate
occasions, 5 repeated bouts of cycle ergometry (15 seconds in duration with an active rest 
period of 45 seconds between bouts) and that for 3 hours leading up to this test, that I will 
have refrained from ingesting food, caffeine, and/or alcohol. I sign this form with the 
knowledge that I may experience a brief period of muscular fatigue in my legs and nausea 
following the test.
Finally, I _______________________________ , agree that I may receive either 4 doses
of 5 grams of creatine monohydrate + 2 grams of dextrose powder (sugar) for a period of 
5 days (treatment) or 4 doses of 7 grams of dextrose powder (sugar)for a period of 5 days 
(placebo) as outlined in the accompanying cover letter.
I understand that as a volunteer, I have the right to refose any test and to withdraw from 
study at any time. All information collected for the purpose of this research will remain 
confrdentiW through the use of a coding system. No reference of my participation will be 
made in an any report of the results. The data will be stored by Marc Poirier and by Dr. 
Norman Lavoie within the Faculty of Kinesiology for a period of seven years. The findings 
of the study will be made available to me at my request upon completion of the project.
Signature of Participant Date
Signature of Witness Date




I _____________________________ ^4D), have read the research proposal
entitled, “The influence of Type II Muscle Fibers on the Uptake of Creatine and its Effect 
on Repeated Bouts o f Cycle Ergometry” and understand the expectations that are needed
of me in this study. I______________________, furthermore agree to advise all potential
participants of the risks associated with all the procedures outlined in the proposal.
Signature of Medical Doctor Date
Signature of Principle Investigator Date
Signature of Advisor Date
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Appendix E
Please take your time in  filling out this questionnaire as the information is vety important to the results of 
this stucfy. you answer NO to any o f the questions below, please provided as much information as 
possible. It is  more important that as a  researcher, I know exactly w hat the participants did, even if  it was 
not as instructed.
1. In consuming the supplementation, did you follow the instructions provided?
YES □ NO 0
If NO, please specify:__________________________________________________
2. When collecting the 24 hour urine samples, were you able to collect all the urine as asked? 
YES 0  NO 0
If NO, please specify:__________________________________________________
3. When considering your normal level o f physical activity, do you believe it varied significantly
(i.e. intensify, frequency, and/or duration) over the time period o f this study?
YES □ NO 
If NO, please specify:.
4. Did you accurately fill out the nutritional assessment forms provided to you? 
YES □ NO 0
If NO, please specify:______________________________________________
S. Please provide any additional information that you feel is relevant to your participation in this 
study?
YES □ NO 
If NO, please specify:.
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Chapter I : Quantitative dietary assessment
Appendix F
The three-day food record
Dale Day o f the tveek
Subject ID No. Name of Subject






Table X Form used to record detailed food intakes.
- 9 -  i
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Appendix G
Table 17. Statistical Data for a 2 x 2 x 2 Factorial ANOVA with body mass as the
Source SS d f M S F-value Significance
WAnT 452.16 1 452.16 1.0 0.33
Treatment 57.01 I 57.01 0.13 0.73
WAnT X Treatment 9.96 1 9.96 0.02 0.88
Error-Between Groups 6723.12 15 448.21 ----- -----
Time 3.75 I 3.75 7.17 0.02
Time x WAnT 0.03 1 0.03 0.07 0.80
Time x Treatment 0.49 1 0.49 0.94 0.35
Time x WAnT x Treatment 0.24 1 0.24 0.47 0.50
Error-W itbin Groups 7.84 15 0.52 ---- ----
Table 18. Statistical Data for a 2 x 2 x 2 Factorial ANOVA with protein intake as the
Source SS d / M S F-value Significance
WAnT 155.34 1 155.34 0.26 0.62
Treatment 107.36 1 107.36 0.18 0.68
WAnT X Treatment 656.47 1 656.47 1.07 0.32
Error-Between Groups 9134.25 15 608.95 ----- -----
Time 35.29 1 35.29 0.57 0.46
Time x WAnT 32.57 1 32.57 0.52 0.48
Time x Treatment 6.64 1 6.64 0.11 0.75
Time x WAnT x Treatment 4.66 1 4.66 0.08 0.79
Enor-W itbin Groups 932.79 15 62.18 ---- ----
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Table 24 Statistical Data for a 2 x 2 x S Factorial ANOVA with PAPr (change score) as
Source SS d f M S F-value Significance
WAnT 1.36 1 1.36 2.64 0.13
Treatment 0.73 1 0.73 1.42 0.25
WAnT X Treatment 0.16 1 0.16 0.32 0.58
Error-Between Groups 7.73 15 0.52 ----- — «1
Bouts 0.89 2.32 0.38 0.85 0.45
Bouts X WAnT 1.19 2.32 0.51 1.12 0.34
Bouts X Treatment 0.19 2.32 0.08 0.18 0.87
Bouts X WAnT x Treatment 0.37 2.32 0.14 0.31 0.77
Error-W ithin Groups 15.78 34.73 0.45 ---- -----
Table 25. Statistical Data for a 2 x 2 x 5 Factorial ANOVA with PAPa (change score) as
Source SS D f M S F-value Significance
WAnT 13785.46 1 13785.46 3.09 0.10
Treatment 10740.31 1 10740.31 2.41 0.14
WAnT X Treatment 1989.37 1 1989.37 0.45 0.51
Error-Between Groups 66835.99 15 4455.73 ----- -----
Bouts 7076.62 2.18 3247.22 0.97 0.40
Bouts X WAnT 6836.47 2.18 3137.00 0.94 0.41
Bouts X Treatment 1990.70 2.18 913.47 0.27 0.78
Bouts X WAnT x Treatment 3825.18 2.18 1755.24 0.52 0.61
Error-W ithin Groups 109606.36 32.69 3352.98 ----- ----
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Table 26. Statistical Data for a 2 x 2 x 5 Factorial ANOVA with MAPr (change score) as 
the deoendent measure.
Source SS d f M S F-value Significance
WAnT 1.54 1 1.54 2.05 0.17
Treatment 0.65 1 0.65 0.87 0.38
WAnT X Treatment 0.30 1 0.30 0.40 0.54
Error-Between Groups 11.25 15 0.75 ----- -----
Bouts 0.83 4 0.21 1.83 0.13
Bouts X WAnT 0.24 4 0.09 0.53 0.72
Bouts X Treatment 0.18 4 0.06 0.38 0.82
Bouts X WAnT x Treatment 0.43 4 0.17 0.95 0.44
Error-W ithin Groups 6.79 60 0.18 ----- -----
Table 27. Statistical Data for a 2 x 2 x 5 Factorial ANOVA with MAPa (change score) as 
the dependent measure.
Source SS d f M S F-value Significance
WAnT 17491.29 1 17491.29 2.00 0.18
Treatment 8552.36 1 8552.36 0.98 0.34
WAnT X Treatment 3774.17 1 3774.17 0.43 0.92
Error-Between Groups 130971.27 15 8731.42 ----- -----
Bouts 4960.61 4 1240.15 1.39 0.25
Bouts X WAnT 3207.13 4 801.78 0.90 0.47
Bouts X Treatment 763.13 4 190.78 0.21 0.93
Bouts X WAnT x Treatment 4303.46 4 1075.86 1.20 0.32
Error-W ithin Groups 53433.88 60 890.57
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Table 28. Statistical Data for a 2 x 2 x 5 Factorial ANOVA with FI (change score) as the
Source SS d f MS F-value Significance
WAnT 6.24 1 6.24 0.05 0.82
Treatment 27.19 1 27.19 0.27 0.63
WAnT X Treatment 212.47 1 212.47 1.84 0.19
Error-Between Groups 1728.31 15 115.22 -----
Bouts 118.77 4 29.69 0.87 0.49
Bouts X WAnT 175.99 4 43.99 1.29 0.28
Bouts X Treatment 6.38 4 1.59 0.05 0.99
Bouts X WAnT x Treatment 66.09 4 16.52 0.49 0.75
Error-W ithin Groups 2037.74 60 33.96 ---- ----
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Appendix H
It should be noted that when a repeated measures factorial ANOVA is calculated, 
Mauchly's test of sphericity is performed. If  this test is significant, than the probabilities 
associated with the F value need correction by multiplying the degrees of fi-eedom by the 
value o f Greenhouse-Geisser epsilon (Puri, 1996). Appendix G provides the results of 
Mauchly's test of sphericity, also known as Mauchly's W, for each of the five dependent 
variables, with only PAPr and PAPa being significant. Therefore, the appropriate 
corrections were performed to the degrees of fi-eedom and the probabilities for these 
dependent measures.
Results o f Mauchly's test of Sphericity
Maulchÿs W Degrees of Freedom Significance Greenhouse-Geisser Epsilon
PAPr .155 9 .003* .579
PAPa .141 9 .002* .545
MAPr .288 9 .056 .618
MAPa .354 9 .127 .684
%PD .399 9 .198 .717
"‘significant at the 0.05 level
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